The degree to which BLOOD VESSELS are not blocked or obstructed.
Methods for assessing the patency of the fallopian tubes.
Obstruction of flow in biological or prosthetic vascular grafts.
Surgical shunt allowing direct passage of blood from an artery to a vein. (From Dorland, 28th ed)
Homopolymer of tetrafluoroethylene. Nonflammable, tough, inert plastic tubing or sheeting; used to line vessels, insulate, protect or lubricate apparatus; also as filter, coating for surgical implants or as prosthetic material. Synonyms: Fluoroflex; Fluoroplast; Ftoroplast; Halon; Polyfene; PTFE; Tetron.
The continuation of the femoral artery coursing through the popliteal fossa; it divides into the anterior and posterior tibial arteries.
The main artery of the thigh, a continuation of the external iliac artery.
Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels.
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Agents that prevent clotting.
Catheters designed to be left within an organ or passage for an extended period of time.
Devices to be inserted into veins or arteries for the purpose of carrying fluids into or from a peripheral or central vascular location. They may include component parts such as catheters, ports, reservoirs, and valves. They may be left in place temporarily for therapeutic or diagnostic purposes.
Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.
The vein which drains the foot and leg.
Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
Radiography of the vascular system of the heart muscle after injection of a contrast medium.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Use of a balloon catheter for dilation of an occluded artery. It is used in treatment of arterial occlusive diseases, including renal artery stenosis and arterial occlusions in the leg. For the specific technique of BALLOON DILATION in coronary arteries, ANGIOPLASTY, BALLOON, CORONARY is available.
The condition of an anatomical structure's being constricted beyond normal dimensions.
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
Vein formed by the union (at the hilus of the spleen) of several small veins from the stomach, pancreas, spleen and mesentery.
Surgical removal of the pancreas. (Dorland, 28th ed)
The largest branch of the celiac trunk with distribution to the spleen, pancreas, stomach and greater omentum.
Techniques, procedures, and therapies carried out on diseased organs in such a way to avoid complete removal of the organ and preserve the remaining organ function.
Insufficiency of arterial or venous blood supply to the spleen due to emboli, thrombi, vascular torsion, or pressure that produces a macroscopic area of necrosis. (From Stedman, 25th ed)
A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY. If appropriate, biopsy or surgery can be performed during laparoscopy.
The prevention of access by infecting organisms to the locus of potential infection.
Genetically developed small pigs for use in biomedical research. There are several strains - Yucatan miniature, Sinclair miniature, and Minnesota miniature.
A phenothiazine that is used in the treatment of PSYCHOSES.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
Diet modification and physical exercise to improve the ability of animals to perform physical activities.
A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.)
A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55.
A dipolar ionic buffer.
The rate dynamics in chemical or physical systems.
A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed)
Glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters.

Infrainguinal revascularisation in the era of vein-graft surveillance--do clinical factors influence long-term outcome? (1/2062)

OBJECTIVES: To investigate the variables affecting the long-term outcome of infrainguinal vein bypass grafts that have undergone postoperative surveillance. DESIGN: A retrospective analysis. PATIENTS AND METHODS: Details of 299 consecutive infrainguinal vein grafts performed in 275 patients from a single university hospital were collected and analysed. All grafts underwent postoperative duplex surveillance. Factors affecting patency, limb salvage and survival rates were examined. These factors were gender, diabetes, hypertension, aspirin, warfarin, ischaemic heart disease, run-off, graft type, early thrombectomy, level of anastomoses and indication for surgery. RESULTS: The 6-year primary, primary assisted and secondary patency rates were 23, 47, and 57%, respectively. Six-year limb salvage and patient survival were 68 and 45%, respectively. Primary patency was adversely influenced by the use of composite vein grafts. Early thrombectomy was the only factor that significantly influenced secondary patency. Limb salvage was worse in diabetic limbs, limbs with poor run-off and in grafts that required early thrombectomy. Postoperative survival was better in males, claudicants and in patients who took aspirin. CONCLUSIONS: Although co-morbid factors did not influence graft patency rates, diabetes did adversely effect limb salvage. This study, like others before it, confirms that aspirin significantly reduces long-term mortality in patients undergoing infrainguinal revascularisation.  (+info)

Isolated femoropopliteal bypass graft for limb salvage after failed tibial reconstruction: a viable alternative to amputation. (2/2062)

PURPOSE: Femoropopliteal bypass grafting procedures performed to isolated popliteal arteries after failure of a previous tibial reconstruction were studied. The results were compared with those of a study of primary isolated femoropopliteal bypass grafts (IFPBs). METHODS: IFPBs were only constructed if the uninvolved or patent popliteal segment measured at least 7 cm in length and had at least one major collateral supplying the calf. When IFPB was performed for ischemic lesions, these lesions were usually limited to the digits or small portions of the foot. Forty-seven polytetrafluoroethylene grafts and three autogenous reversed saphenous vein grafts were used. RESULTS: Ankle brachial pressure index (ABI) increased after bypass grafting by a mean of 0.46. Three-year primary life table patency and limb-salvage rates for primary IFPBs were 73% and 86%, respectively. All eight IFPBs performed after failed tibial bypass grafts remained patent for 2 to 44 months, with patients having viable, healed feet. CONCLUSION: In the presence of a suitable popliteal artery and limited tissue necrosis, IFPB can have acceptable patency and limb-salvage rates, even when a polytetrafluoroethylene graft is used. Secondary IFPB can be used to achieve limb salvage after failed tibial bypass grafting.  (+info)

Superficial femoral eversion endarterectomy combined with a vein segment as a composite artery-vein bypass graft for infrainguinal arterial reconstruction. (3/2062)

OBJECTIVE: The purpose of this study was to determine the results of composite artery-vein bypass grafting for infrainguinal arterial reconstruction. METHODS: This study was designed as a retrospective case series in two tertiary referral centers. Forty-eight of 51 patients underwent the procedure of interest for the treatment of ischemic skin lesions (n = 42), rest pain (n = 3), disabling claudication (n = 1), and infected prosthesis (n = 2). The intervention used was infrainguinal composite artery-vein bypass grafting to popliteal (n = 18) and infrapopliteal (n = 30) arteries, with an occluded segment of the superficial femoral artery prepared with eversion endarterectomy and an autogenous vein conduit harvested from greater saphenous veins (n = 43), arm veins (n = 3), and lesser saphenous veins (n = 2). The main outcome measures, primary graft patency rates, foot salvage rates, and patient survival rates, were described by means of the life-table method for a mean follow-up time of 15.5 months. RESULTS: The cumulative loss during the follow-up period was 6% and 24% at 6 and 12 months, respectively. The primary graft patency rates, the foot salvage rates, and the patient survival rates for patients with popliteal grafts were 60.0% +/- 9.07%, 75.7% +/- 9.18%, and 93.5% +/- 6.03%, respectively, at 1 month; 53.7% +/- 11.85%, 68.9% +/- 12.47%, and 85. 0% +/- 9.92% at 1 year; and 46.7% +/- 18.19%, 68.9% +/- 20.54%, and 53.1% +/- 17.15% at 5 years. For infrapopliteal grafts, the corresponding estimates were 72.4% +/- 7.06%, 72.9% +/- 6.99%, and 92.7% +/- 4.79% at 1 month; 55.6% +/- 10.70%, 55.4% +/- 10.07%, and 77.9% +/- 9.02% at 1 year; and 33.6% +/- 22.36%, 55.4% +/- 30.20%, and 20.8% +/- 9.89% at 5 years. CONCLUSION: The composite artery-vein bypass graft is a useful autogenous alternative for infrainguinal arterial reconstruction when a vein of the required quality is not available or when the procedure needs to be confined to the affected limb.  (+info)

Surgical transluminal iliac angioplasty with selective stenting: long-term results assessed by means of duplex scanning. (4/2062)

PURPOSE: The safety of iliac angioplasty and selective stenting performed in the operating room by vascular surgeons was evaluated, and the short- and long-term results were assessed by means of serial duplex scanning. METHODS: Between 1989 and 1996, 281 iliac stenotic or occlusive lesions in 235 consecutive patients with chronic limb ischemia were treated by means of percutaneous transluminal angioplasty (PTA) alone (n = 214) or PTA with stent (n = 67, 23.8%). There were 260 primary lesions and 21 restenosis after a first PTA, which were analyzed separately. Stents were implanted in selected cases, either primarily in totally occluded arteries or after suboptimum results of PTA (ie, residual stenosis or a dissection). Data were collected prospectively and analyzed retrospectively. Results were reported in an intention-to-treat basis. Clinical results and patency were evaluated by means of symptom assessment, ankle brachial pressure index, and duplex scanning at discharge and 1, 3, 6, and every 12 months after angioplasty. To identify factors that may affect outcome, 12 clinical and radiological variables, including the four categories of lesions defined by the Standards of Practice Committee of the Society of Cardiovascular and Interventional Radiology, were analyzed separately. The statistical significances of life-table analysis of patency were determined by means of the log-rank test. RESULTS: There were no postoperative deaths or amputations. Local, general, and vascular complications occurred in 2.1%, 1.3% and 4.7% of cases, respectively (total, 8.1%). The mean follow-up period was 29.6 months. The cumulative patency rates +/- SE of the 260 PTAs (including 55 PTAs plus stents) were 92.9% +/- 1.5% at 1 month, 86. 5% +/- 1.7% at 1 year, 81.2% +/- 2.3% at 2 years, 78.8% +/- 2.9% at 3 years, and 75.4% +/- 3.5% at 5 and 6 years. The two-year patency rate of 21 redo PTAs (including 11 PTAs plus stents) was 79.1% +/- 18.2%. Of 12 predictable variables studied in the first PTA group, only the category of the lesion was predictive of long-term patency. The two-year patency rate was 84% +/- 3% for 199 category 1 lesions and 69.7% +/- 6.5% for 61 category 2, 3, and 4 lesions together (P =. 02). There was no difference of patency in the stented and nonstented group. CONCLUSION: Iliac PTA alone or with the use of a stent (in cases of occlusion and/or suboptimal results of PTA) offers an excellent long-term patency rate. Categorization of lesions remains useful in predicting long-term outcome. PTA can be performed safely by vascular surgeons in the operating room and should be considered to be the primary treatment for localized iliac occlusive disease.  (+info)

Right atrial bypass grafting for central venous obstruction associated with dialysis access: another treatment option. (5/2062)

PURPOSE: Central venous obstruction is a common problem in patients with chronic renal failure who undergo maintenance hemodialysis. We studied the use of right atrial bypass grafting in nine cases of central venous obstruction associated with upper extremity venous hypertension. To better understand the options for managing this condition, we discuss the roles of surgery and percutaneous transluminal angioplasty with stent placement. METHODS: All patients had previously undergone placement of bilateral temporary subclavian vein dialysis catheters. Severe arm swelling, graft thrombosis, or graft malfunction developed because of central venous stenosis or obstruction in the absence of alternative access sites. A large-diameter (10 to 16 mm) externally reinforced polytetrafluoroethylene (GoreTex) graft was used to bypass the obstructed vein and was anastomosed to the right atrial appendage. This technique was used to bypass six lesions in the subclavian vein, two lesions at the innominate vein/superior vena caval junction, and one lesion in the distal axillary vein. RESULTS: All patients except one had significant resolution of symptoms without operative mortality. Bypass grafts remained patent, allowing the arteriovenous grafts to provide functional access for 1.5 to 52 months (mean, 15.4 months) after surgery. CONCLUSION: Because no mortality directly resulted from the procedure and the morbidity rate was acceptable, this bypass grafting technique was adequate in maintaining the dialysis access needed by these patients. Because of the magnitude of the procedure, we recommend it only for the occasional patient in whom all other access sites are exhausted and in whom percutaneous dilation and/or stenting has failed.  (+info)

Relief of obstructive pelvic venous symptoms with endoluminal stenting. (6/2062)

PURPOSE: To select patients for percutaneous transluminal stenting of chronic postthrombotic pelvic venous obstructions (CPPVO), we evaluated the clinical symptoms in a cohort of candidates and in a series of successfully treated patients. METHODS: The symptoms of 42 patients (39 women) with CPPVO (38 left iliac; average history, 18 years) were recorded, and the venous anatomy was studied by means of duplex scanning, subtraction venography, and computed tomography or magnetic resonance imaging. Successfully stented patients were controlled by means of duplex scanning and assessment of symptoms. RESULTS: The typical symptoms of CPPVO were reported spontaneously by 24% of patients and uncovered by means of a targeted interview in an additional 47%. Of 42 patients, 15 had venous claudication, four had neurogenic claudication (caused by dilated veins in the spinal canal that arise from the collateral circulation), and 11 had both symptoms. Twelve patients had no specific symptoms. Placement of a stent was found to be technically feasible in 25 patients (60%), was attempted in 14 patients, and was primarily successful in 12 patients. One stent occluded within the first week. All other stents were fully patent after a mean of 15 months (range, 1 to 43 months). Satisfaction was high in the patients who had the typical symptoms, but low in those who lacked them. CONCLUSION: Venous claudication and neurogenic claudication caused by venous collaterals in the spinal canal are typical clinical features of CPPVO. We recommend searching for these symptoms, because recanalization by means of stenting is often feasible and rewarding.  (+info)

Use of high-intensity focused ultrasound to control bleeding. (7/2062)

OBJECTIVE: High-intensity focused ultrasound (HIFU) has been shown to be effective in controlling hemorrhage from punctures in blood vessels. The objective of the current study was to investigate the capability of HIFU to stop bleeding after a more severe type of vascular injury, namely longitudinal incisions of arteries and veins. METHODS: The superficial femoral arteries, common femoral arteries, carotid arteries, and jugular veins of four anesthetized pigs were exposed surgically. A longitudinal incision, 2 to 8 mm in length, was produced in the vessel. HIFU treatment was applied within 5 seconds of the onset of the bleeding. The HIFU probe consisted of a high-power, 3.5-MHz, piezoelectric transducer with an ellipsoidal focal spot that was 1 mm in cross section and 9 mm in axial dimension. The entire incision area was scanned with the HIFU beam at a rate of 15 to 25 times/second and a linear displacement of 5 to 10 mm. A total of 76 incisions and HIFU treatments were performed. RESULTS: Control of bleeding (major hemosatsis) was achieved in all 76 treatments, with complete hemostasis achieved in 69 treatments (91%). The average treatment times of major and complete hemostasis were 17 and 25 seconds, respectively. After the treatment, 74% of the vessels in which complete hemostasis was achieved were patent with distal blood flow and 26% were occluded. The HIFU-treated vessels showed a consistent coagulation of the adventitia surrounding the vessels, with a remarkably localized injury to the vessel wall. Extensive fibrin deposition at the treatment site was observed. CONCLUSION: HIFU may provide a useful method of achieving hemostasis for arteries and veins in a variety of clinical applications.  (+info)

Hemodialysis access: influence of the human immunodeficiency virus on patency and infection rates. (8/2062)

PURPOSE: The complication rate for patients who are dialysis dependent and infected with the human immunodeficiency virus (HIV) and the role of viral indicators (CD4 counts) as predictors of these complications are poorly characterized. To determine the influence of HIV status and viral activity on graft patency and infection rates, we retrospectively reviewed our results. METHODS: Between June 1993 and March 1997, the charts of 104 patients (HIV+, n = 42; HIV-, n = 62) who required 112 hemodialysis access grafts were reviewed. Of the 112 procedures, 55 (48%) were autologous arteriovenous fistulae (AVF) procedures (HIV+, n = 23; HIV-, n = 32) and 57 (52%) were prosthetic expanded polytetrafluoroethylene grafting procedures (HIV+, n = 27; HIV-, n = 30). Transcutaneous catheter procedures were excluded from the study. The autologous AVF procedures consisted of direct and transposed AVFs. Patency rates were determined by means of life-table analysis. Infection rates and CD4 counts were compared with the chi2 test and the Fisher exact test. Significance was accepted at a P value of.05 or less. RESULTS: The cumulative 12-month and 24-month patency rates for prosthetic grafts in patients who were HIV+ were 49% and 21%, respectively, versus 77% and 45% for patients who were HIV-. The differences in the prosthetic graft patency rates between these two groups were significant (P .05). The mean CD4+ cell counts were 174: CD4+ counts that were less than 200 did not correlate with or predict the development of infection (P >.05). CONCLUSION: Our data showed that prosthetic graft infection rates were increased and patency rates were decreased in patients who were HIV+ as compared with patients who were HIV- and HIV+ with autologous AVFs. There were no differences in patency rates or infection rates in patients who had undergone autologous access procedures. Long-term graft patency rates were not affected by HIV status, and CD4+ lymphocyte counts were not predictive of infection development. Because the prosthetic graft infection rates exceeded those rates of autologous access procedures, we recommend the vigorous use of autologous AVFs in all patients who are HIV+, regardless of CD4+ count.  (+info)

Sep 28, 2015. MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate. New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more than 96 percent. These results represent the highest 12-month primary patency reported for an interventional treatment of femoropopliteal artery lesions among comparable trials. The Eluvia Stent System is an advanced treatment option for patients with narrowing or blockages in the superficial femoral artery (SFA) or proximal popliteal artery (PPA), a result of peripheral artery disease (PAD).. Results from the MAJESTIC trial, which were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting in Lisbon, Portugal, also included a low 12-month target lesion revascularization (TLR) rate of 3.8 percent, with no observed stent fractures and no ...
The Particulars: Previous research has not established the success rate for stenting of the superficial femoral artery (SFA).. Data Breakdown: An investigation conducted in Germany was performed, involving 517 patients who received 827 SFA stents in 543 limbs. More than three-quarters of patients (78%) were treated for claudication, and the remainder were treated for critical limb ischemia (CLI). At 1, 3, and 5 years, primary patency rates were 86%, 75%, and 61%, respectively. Secondary patency rates at the same time points were 95%, 90%, and 76%. At an average of 93.4 months follow up, 18.8% of patients died.. Take Home Pearl: More than half of patients treated with SFA stents for claudication or CLI appear to retain primary patency with their stents when assessed at 5 years. ...
Miromatrix will present its latest transplantable liver milestone at The Liver Meeting® hosted by the American Association for the Study of Liver Diseases (AASLD) on October 20-24 in Washington, D.C. Building on the companys successful liver re-endothelialization efforts, Miromatrix has advanced its ability to demonstrate functional liver vasculature by maintaining long-term vascular patency of its engineered liver grafts in a porcine model. A poster describing these advancements entitled Towards Long-Term Vascular Patency of Tissue Engineered Liver Grafts: a Large Animal Study will be presented at the conference on October 20th (Poster #712). Twenty-seven porcine liver grafts were seeded with endothelial cells cultured in bioreactors, 20 of which were evaluated in vitro to determine important factors that predict in vivo vascular patency. Grafts with higher glucose consumption rate (GCR) had evidence of better endothelial coverage (p=0.012) and correlated significantly with graft flow ...
Aim. Randomized studies evaluating the effect of a vein collar at the distal anastomosis of PTFE-grafts show conflicting results. The study of the Joint Vascular Research Group (JVRG) of UK found improved primary patency while the Scandinavian Miller Collar Study (SCAMICOS) found neither any effect on patency nor on limb salvage after bypass to below-knee arteries. However, the Scandinavian patients were a decade older and predominately female compared to the British patients. Can this explain the conflicting result? less thanbrgreater than less thanbrgreater thanMethods: Primary patency with respect to sex, age and the use of vein collar were re-analysed in 345 patients from SCAMICOS with Kaplan-Meier life-table technique, log-rank test and Cox proportional hazards regression to evaluate any interaction between sex or age and the effect of a vein collar on the primary patency rate. less thanbrgreater than less thanbrgreater thanResults. Females had better patency than males (log-rank test, ...
Besides the main result (similar patency of the beating-heart grafts and classic on-pump grafts), the most surprising finding in this study was the low saphenous graft patency in both study groups. This can be explained by the fact that this study was meticulously prepared not to allow cardiac surgeon to influence patient selection for the study. Thus, this study reflects the real-life everyday practice of cardiac surgery at the beginning of the 21st century. This means that almost all patients with good-quality vessels (ie, vessels ,2 mm, without heavy diffuse calcifications, without chronic total occlusions) are treated by percutaneous coronary interventions. Thus, the current cardiac surgery patient population consists of patients not suitable for angioplasty-the most advanced coronary artery disease cases. Most of the older trials investigating angiographic bypass graft patency after classic on-pump surgery were done 10 to 20 years ago, well before the modern stent era. Thus, they enrolled ...
Haskal ZJ, Saad TF, Hoggard JG, Cooper RI, Lipkowitz GS, Gerges A, Ross JR, Pflederer TA, Mietling SW. Prospective, Randomized, Concurrently-Controlled Study of a Stent Graft versus Balloon Angioplasty for Treatment of Arteriovenous Access Graft Stenosis: 2-Year Results of the RENOVA Study. J Vasc Interv Radiol. 2016 Aug; 27(8):1105-1114.e3 ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Parent vessel patency and incidence of different flow patterns over the course of two weeks after mini port implantation in mice.
Remi Bloston is the new hot product on the European market. It is very likely that it will be the best-selling supplement that treats cardiovascular issues this year!
A method for implanting an end portion of a graft within the body of a patient during a bypass grafting procedure includes the steps of (1) making an arteriotomy in a sidewall of a blood vessel at a f
CINAR BAYER , GOKSEL ONUR S. , YEKELER IBRAHIM THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE 207(3), 233-238, 2005-11-01 医中誌Web 参考文献15件 被引用文献1件 ...
Aortocoronary bypass graft failure is common and is associated with high morbidity and mortality. Failure of saphenous vein grafts is more common than failure of internal mammary artery grafts. Whether early graft angiography can reduce bypass graft failure remains unknown. The Cardiac CAtheterization for Bypass Graft Patency Rate Optimization (CABG-PRO) randomized-controlled pilot study is a phase III, double-blind, randomized-controlled pilot trial that will randomize 170 patients undergoing coronary artery bypass graft surgery to early (before dismissal) graft angiography vs. no early graft angiography. Coronary angiography will be performed at 12 months, to determine whether compared to no early graft angiography, early graft angiography will result in:. ...
Aortocoronary bypass graft failure is common and is associated with high morbidity and mortality. Failure of saphenous vein grafts is more common than failure of internal mammary artery grafts. Whether early graft angiography can reduce bypass graft failure remains unknown. The Cardiac CAtheterization for Bypass Graft Patency Rate Optimization (CABG-PRO) randomized-controlled pilot study is a phase III, double-blind, randomized-controlled pilot trial that will randomize 170 patients undergoing coronary artery bypass graft surgery to early (before dismissal) graft angiography vs. no early graft angiography. Coronary angiography will be performed at 12 months, to determine whether compared to no early graft angiography, early graft angiography will result in:. ...
Licht et al reported a series of 39 patients undergoing coronary artery bypass grafting(CABG) who had a cephalic vein. 18 had angiographic follow up (mean 31 months). 52% of grafts were patent, 39% of all veins had intraluminal disease, and 19% were dilated. Wijnberg et al compared a group of 28 patients who received a cephalic vein graft with a matched group who received saphenous vein grafts. At mean 4.6 year follow up, cephalic vein patency was 47% compared to 77%. Stoney et al assessed the patency of 56 cephalic or basilic vein grafts from 28 patients. 32/56(57%) grafts were patent at mean 25 months while 7(12.5%) of the patent grafts had localised stenoses. Jarvinen et al reported the patency of 16 cephalic veins in 15 patients. At a mean follow up of 1.4 years (1-42 months), 87% (27/31 distal anastomoses) were patent angiographically although 3 veins also had aneurysmal dilatation. Prieto et al examined ten patients at different intervals. The early patency of arm vein grafts in six ...
HypothesisPercutaneous angioplasty would provide a durable alternative to surgical revision in the treatment of infrainguinal vein graft stenosis.DesignOutcome
Cryopreserved allografts have demonstrated resistance to infection similar to that of autogenous tissue when used for the treatment of prosthetic arterial bypass graft infections. As the number of hemodialysis access procedures increases, prosthetic hemodialysis graft infection has become a significant problem. We have used the cryopreserved femoral vein as an alternative conduit in the treatment of prosthetic arteriovenous (AV) hemodialysis graft infections. Forty-eight cryopreserved femoral vein AV graft procedures were performed. The 1-year primary graft patency rate was 49%, while the secondary graft patency rate was 75%. No subsequent cryopreserved allograft infections occurred. The cryopreserved femoral vein graft is a safe, durable, and infection resistant conduit for the treatment of prosthetic AV hemodialysis graft infections.
We have reviewed our experience with the tibial vessel bypass operation and have found the overall patency and limb salvage rates to be acceptable. Patients were divided into two groups based on the site of the proximal anastomosis. In Group I, the proximal anastomosis was at the common femoral artery and in Group II, the proximal anastomosis was at the distal superficial femoral artery or the popliteal artery. The patients in the the two groups were similar with regard to indications for operation, age, and sex. However, in Group I, 35 percent of the patients were diabetic and in Group II, 74 percent of the patients were diabetic. In the Group I patients, the 72 month graft patency rate was 65 percent with a limb salvage rate of 75 percent. In the Group II patients, the 72 month patency rate was 81 percent with a limb salvage rate of 89 percent. Some possible explanations for this slightly better result in Group II patients are discussed. All tibial bypasses were divided into three groups based on the
Autologous saphenous vein continues to be one of the most widely used conduits for myocardial revascularization7 despite its disappointing long-term patency rate, with ≤50% of vein grafts occluded by 10 years after surgery.8 9 Late occlusion appears to result from both medial and neointimal thickening, caused by migration and proliferation of smooth muscle cells, and the late appearance of mature lipid-laden atherosclerotic plaques. These changes can compromise flow directly or promote thrombotic occlusion.1 10 Neither antiplatelet therapy nor avoidance of surgical preparative injury has been shown conclusively to eliminate medial and neointimal thickening in either experimental models or human vein grafts.1 2 8 Vessel wall thickening may be regarded as an intrinsic adaptation of the vein to arterial pressure,1 10 and grafting per se was recently shown to stimulate the production of endogenous growth factors from pig saphenous vein, which may account for the platelet independence of graft wall ...
In this issue of the Journal, Gaudino et al. (1) report on an interesting and fairly unique study describing the 20-year patency and outcomes in their initial series of 100 patients who received a radial artery (RA) graft, and who were prospectively followed. Previous long-term follow-up series of the RA as a coronary artery bypass graft (CABG) included those from Achouh et al. (2), Shi et al. (3), and the investigators of the Gaudino paper themselves (4). The main strength of the present study is the pre-specified systematic assessment of graft patency and RA harvest-related arm complications at specific time points, with a long period of follow-up.. All studies that deal primarily with long-term graft patency have inherent weaknesses. Because it is virtually impossible to have all patients return for long-term invasive coronary anatomy and graft assessment, various methodological approaches may be used to estimate true conduit patency. Some authors choose to ignore, that is censor, patients ...
PURPOSE: To evaluate the influence of serum lipid subfraction concentrations on arterial patency after percutaneous transluminal angioplasty (PTA) in patients with infrainguinal peripheral artery occlusive disease (PAOD). METHODS: From January 2007 t
This study shows that in patients randomly treated with either an RGEA or an SVG for a stenosis of the RCA, the proportion of grafts found occluded on systematic 6-month angiographic control is low and independent of the type of graft conduit; however, the flow pattern is significantly more affected by the angiographic characteristics of the grafted RCA for RGEA than for SVG. Consequently, most SVG but only a minority of RGEA remained functional when the MLD of the RCA was larger than a threshold value close to 1.0 mm.. Previous angiographic follow-up studies of RGEA have suggested that the graft patency might be affected by the stenosis of the recipient RCA, most likely as a result of competitive flow (3,15,16). The evaluation of stenosis severity was based on visual interpretation of post-operative coronary angiogram at the time of angiographic follow-up. In the present study, the evaluation of RCA stenosis severity was done on pre-operative angiogram to eliminate the possible influence of ...
Introduction: Acknowledging the superior long term patency of infrainguinal saphenous bypass to distal popliteal artery, debate continues regarding the choice of alternative conduits and possible surgical adjuncts to improve inflow and graft salvage. The objective of this retrospective study was to determine the effectiveness of proximal anastomotic patch as adjunct to open surgical below the knee popliteal revascularization.. Material and Methods: In a series of 132 distal popliteal bypass operations 63 non-reversed vein, 18 in situ vein and 51 Omniflow bypass conduits were used. Proximal anastomotic patch was applied in overall 28 patients: 19% in the non-reversed (12 patients), 50% in the in situ group (9 patients) and 13.7% in the Omniflow group (7 patients).. Results: The reintervention rate was 7.9% in the non-reversed, 33.3% in the in situ and 31.4% in the Omniflow group. The most often complication was the proximal anastomotic stenosis (5.3%), followed by bleeding (3%), infection (1.5%) ...
In comparison to medical treatment and PCI, CABG surgery undoubtedly reduces angina severity and frequency in at least 80- 85% of patients. Though coronary artery bypass surgery has stood the test of time, its success mainly depends on the long term patency of the grafts.. Recurrent limiting angina after CABG, however, has been a major challenge to the treating surgeon and physician. To patients, it is much more grievous than mortality. In our center, there were a total of 80 patients present with refractory angina after CABG surgery from 2014 till 2019. Despite optimal medical management, the other option is revascularization, either PCI or redo surgery. Redo- CABG is often fraught by patients due to its high mortality risk, 2-3 times higher than the first surgery with relatively less promising angina alleviation. Redo- CABG is associated with greater risk of bleeding, exploration difficulty due to adhesions, and potential injury to the existing grafts. Therefore, redo- CABG is only limited to ...
According to his study-Stent graft vs. balloon angioplasty for failing dialysis-access grafts- published in the New England Journal of Medicine, anatomic success with the stent graft compared to percutaneous transluminal angioplasty was 94% and 73% respectively. At six months, Haskal explained, binary restenosis was 27.63% for the stent graft and 77.61% for angioplasty.. He also noted that the 12-month reintervention rate to maintain patency was 1.9% for the stent graft and 2.4% for angioplasty. The 12-month index of patency function was 5.3% for the stent graft and 4.4% for angioplasty, for access circuit primary patency it was 24.1% and 10.3%, and for treatment area primary patency it was 4.7% and 24.8% respectively. The latter was statistically significant (p,0.001).. Results of the study exceeded our expectations, and that is a boon for dialysis patients, said Haskal. Dialysis is very demanding, and anything that prevents access sites from failing and reduces the need for invasive ...
November 23, 2016-Biotronik announced that interim data from the BIOFLEX PEACE all-comers trial, which confirm the efficacy of the companys Pulsar-18 bare-metal, self-expanding stent (BMS SE) in the treatment of superficial femoral artery (SFA) disease, were presented at the 43rd annual VEITHsymposium, which was held November 15-19, 2016, in New York, New York. Jos C. van den Berg, MD, from Ospedale Regionale di Lugano, Switzerland, presented the results for Pulsar-18 during the symposiums main program on behalf of the trials lead investigator, Michael Lichtenberg, MD, of the Vascular Center, Arnsberg, Germany.. BIOFLEX PEACE is a prospective, multicenter registry examining 151 patients in an all-comers enrollment. The studys primary endpoint is primary patency at 12 months.. According to the company, the available 12-month interim results demonstrate that the Pulsar-18 BMS SE is an effective treatment option in the SFA. The primary patency rate of 75% and freedom from target lesion ...
Over a million coronary bypass procedures using human saphenous vein (HSV) are performed yearly worldwide. Nearly half of these grafts fail over a period of 12...
Two-year findings from the VIRTUS trial of the VICI venous stent (Boston Scientific) showed a primary patency rate of 79.4%. As has been seen in other trials, primary patency was higher in non-thrombotic lesions (94.6%) as compared to post-thrombotic lesions (73.4%).
Methods and apparatus for determining the occurrence of an apnea, patency and/or partial obstruction of the airway are disclosed. Respiratory air flow from a patient is measured to give an air flow si
A Stanford neuroscientist is presenting evidence of how chronic stress physically damages a region of the brain that processes learning and memory.
WASHINGTON -- Claudication patients given an investigational self-expanding stent were significantly more likely to maintain vessel patency at 12 months than those treated with percutaneous translumin
Artegraft has been in continuous clinical use since 1970. The first vascular graft approved by the FDA, it has clinically proven higher primary and assisted patency rates over ePTFE grafts.
Envigo has developed an effective method for anchoring the PinPort and has achieved impressive patency information for catheterized animals using the PinPort exteriorization method.
Cells with solid polymer electrolytes have not reached full commercialization and are still a topic of research.[citation needed] Prototype cells of this type could be considered to be between a traditional lithium-ion battery (with liquid electrolyte) and a completely plastic, solid-state lithium-ion battery.[19] The simplest approach is to use a polymer matrix, such as polyvinylidene fluoride (PVdF) or poly(acrylonitrile) (PAN), gelled with conventional salts and solvents, such as LiPF6 in EC/DMC/DEC. Nishi mentions that Sony started research on lithium-ion cells with gelled polymer electrolytes (GPE) in 1988, before the commercialisation of the liquid-electrolyte lithium-ion cell in 1991.[20] At that time polymer batteries were promising and it seemed polymer electrolytes would become indispensable.[21] Eventually, this type of cell went into the market in 1998.[20] However, Scrosati argues that, in the strictest sense, gelled membranes cannot be classified as true polymer electrolytes, but ...
BACKGROUND: We evaluated vascular patency and potential changes in preserved spleens after laparoscopic spleen-preserving distal pancreatectomy (SPDP) with conservation of both splenic vessels.. METHODS: We retrospectively analyzed the patency of conserved splenic vessels in patients who underwent laparoscopic or robotic splenic vessel-conserving SPDP from January 2006 to August 2010. The patency of the conserved splenic vessels was evaluated by abdominal computed tomography and classified into three grades according to the degree of severity.. RESULTS: Among 30 patients with splenic vessel-conserving laparoscopic SPDP, 29 patients with complete follow-up data were included in this study. During the follow-up period (median: 13.2 months), grades 1 and 2 splenic arterial obliteration were observed in one patient each. A total of five patients (17.2%) showed grade 1 or 2 obliteration in conserved splenic veins. Most patients (82.8%) had patent conserved splenic vein. Four patients (13.8%) ...
TY - JOUR. T1 - Predictors of graft patency 3 years after coronary artery bypass graft surgery. AU - Goldman, Steven. AU - Zadina, Karen. AU - Krasnicka, Barbara. AU - Moritz, Thomas. AU - Sethi, Gulshan. AU - Copeland, Jack. AU - Ovitt, Theron. AU - Henderson, William. N1 - Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 1997/6. Y1 - 1997/6. N2 - Objectives. The purpose of this analysis was to define the factors that predict 3-year graft patency. Background. The success of coronary artery bypass graft surgery (CABG) is dependent on vein graft patency after the operation. It has been well established by a series of Department of Veterans Affairs Cooperative Trials that aspirin (325 mg daily) improves saphenous vein graft patency early (7 to 10 days) and at 1 year, but not at 3 years after CABG. This analysis, based on one of these trials, defined factors that predict 3-year graft patency. Methods. This analysis consisted of 266 patients, with 656 grafts that were patent 7 to ...
TY - JOUR. T1 - Noninvasive determination of infarct artery patency by cine magnetic resonance angiography. AU - Hundley, W. G.. AU - Clarke, G. D.. AU - Landau, C.. AU - Lange, R. A.. AU - Willard, J. E.. AU - Hillis, L. D.. AU - Peshock, R. M.. PY - 1995. Y1 - 1995. N2 - Background: In survivors of myocardial infarction, restoration of antegrade flow in the infarct artery reduces morbidity and mortality. At present, coronary artery patency must be assessed invasively with contrast angiography. A noninvasive method of evaluating infarct artery patency would be useful in managing survivors of infarction. This study was performed to determine whether magnetic resonance (MR) imaging could reliably assess infarct artery patency in this patient population. Methods and Results: Eighteen survivors of myocardial infarction (11 men and 7 women, aged 35 to 74 years) who were consecutively referred for cardiac catheterization underwent contrast coronary angiography and cine MR coronary angiography. ...
TY - JOUR. T1 - Long-term angiographic follow-up of robotic-assisted coronary artery revascularization. AU - Currie, Maria E.. AU - Romsa, Jonathan. AU - Fox, Stephanie A.. AU - Vezina, William C.. AU - Akincioglu, Cigdem. AU - Warrington, James C.. AU - McClure, R. Scott. AU - Stitt, Larry W.. AU - Menkis, Alan H.. AU - Boyd, Walter D. AU - Kiaii, Bob. PY - 2012/5. Y1 - 2012/5. N2 - Background: Robotic-assisted coronary artery bypass grafting (CABG) has been shown in short-term studies to increase patient satisfaction and to reduce surgical morbidity and recovery times. However, the long-term patency rate of robotic-assisted CABG is unknown. Therefore, the objective of this study was to assess the long-term patency rate of robotic-assisted coronary artery bypass grafts. Methods: The study cohort included all patients who underwent robotic-assisted conduit dissection for CABG at London Health Sciences Centre between September 1999 and December 2003. These patients had selective graft patency ...
TY - JOUR. T1 - Use of a harvested radial artery graft with preservation of the vena comitantes to reduce spasm risk and improve graft patency for extracranial to intracranial bypass. T2 - Technical note. AU - El Tecle, Najib E.. AU - Zammar, Samer G.. AU - Hamade, Youssef J.. AU - El Ahmadieh, Tarek Y.. AU - Aoun, Rami James N. AU - Nanney, Allan D.. AU - Batjer, Hunt H.. AU - Dumanian, Gregory A.. AU - Bendok, Bernard. PY - 2016/3/1. Y1 - 2016/3/1. N2 - Background and significance: The vessels of choice for cerebrovascular high-flow direct bypass procedures are the radial artery and the saphenous vein. Radial artery grafts have become favored over saphenous vein grafts because of higher patency rates and better size matching to appropriate recipient vessels. Radial grafts are prone to spasm however, and this may be seen in 4-10% of cases and can be associated with ischemic sequelae. The standard technique for radial artery harvest calls for complete separation of the artery from its ...
Objectives: Critical limb ischaemia (CLI) requiring infra-inguinal bypass is a common presentation to the vascular surgery service. A significant number of CLI patients also present with anaemia as a comorbidity, the impact of which is unknown. We reviewed the impact of anaemia on mortality and amputation in patients who underwent infra-inguinal bypass surgery. Methods: Demographic data from all patients who underwent infra-inguinal bypass surgery for CLI at the Flinders Medical Centre & Repatriation General Hospital, South Australia between January 2005 and January 2010 were recorded. Haemoglobin (Hb) level, serum creatinine (SCr) level, mortality and amputation events were also recorded for retrospective analysis. Results: 190 patients (141M, 49F) who underwent infra-inguinal bypass surgery over a 5 year period were analyzed. 100 (53%) of these patients had mild anaemia (mean Hb 113 g/L, mean for females 103 g/L, mean for males 116 g/L). Those who presented with anaemia were more likely to have
Two-stage transposed brachiobasilic arteriovenous fistula is a common procedure after brachiobasilic fistula (BBF) creation. Different techniques can be used for basilic vein transposition but few comparative literature reports are available. The aim of our study was to compare two different techniques for basilic vein transposition. The first maintains the BBF anastomosis and the basilic vein is placed in a subcutaneous pocket (BBAVF). The second transects the basilic vein at the BBF anastomosis and tunnels it superficially, with a new BBF in the brachial artery (BBAVFTn). From 2009 to 2014, all patients who underwent basilic vein superficialization were treated by one of the two techniques, recorded in a dedicated database and retrospectively reviewed. The surgeon chose the technique on the basis of personal preference. The two techniques were compared in terms of perioperative complications, length of hospital stay, time of cannulation, ease of cannulation, and long-term patency. Eighty ...
The final 3-year outcomes of the SUPERB trial showed that use of an interwoven nitinol stent design achieved high primary patency and maintained clinical durability outcomes in patients with lower-limb arterial obstructive disease. “Peripheral artery disease is a growing worldwide epidemic,” Lawrence A. Garcia, MD, from the division of cardiology and vascular medicine at St.
The US Food and Drug Administration has approved the Vici stent for use in treating iliofemoral venous obstructive disease, Boston Scientific announced today. This is the second approval this year for a dedicated venous stent for a disease that has typically been managed in the past with off-label device use. The Vici approval was supported by data from the 170-patient VIRTUS study. As reported by TCTMD earlier this year at ISET 2019, VIRTUS demonstrated a 12-month primary patency rate of 84%, exceeding the performance goal of 72.1% (P , 0.001). Additionally, the Venous Clinical Severity Score (VCSS) declined from 10 at baseline to 5.6 at 12 months, with only 27.3% of patients having a score of 8 or higher.. Vici joins the Venovo (Becton Dickinson) device, which received FDA approval for a similar indication less than 2 months ago based on favorable results from the VERNACULAR trial. As reported by TCTMD at VIVA 2018, VERNACULAR demonstrated a high rate of primary patency at 12 months (88.3%) ...
DISCUSSION. CABG has become the gold standard for the treatment of coronary artery disease involving multiple vessels, and it consists of on-pump CABG and off-pump CABG. In the early 1980s, two surgeons published their extensive series of off-pump CABG in patients who received grafts in the LAD and the main RCA, but with more limited and difficult grafting of coronary arteries on the posterior and lateral walls[15,16]. On-pump CABG provides a motionless operative field, but it can be associated with a number of complications, such as myocardial ischemic injury, strokes, coagulation, and inflammatory responses[17,18]. To the present, it has been reported that the advantage of sequential coronary artery bypass technology is that it can save grafts, reduce proximal anastomosis, shorten the operation time, provide a more complete vascularization, and have a satisfactory long-term patency rate[19,20]. It is more accurate to determine the direction and length of the bridge between anastomoses. There ...
OBJECTIVE--To determine whether concomitant treatment with intravenous heparin affects coronary patency and outcome in patients treated with alteplase thrombolysis for acute myocardial infarction. DESIGN--Double blind randomised trial. TREATMENT REGIMENS--Alteplase 100 mg (not weight adjusted) plus aspirin (250 mg intravenously followed by 75-125 mg on alternate days) plus heparin (5000 units intravenously followed by 1000 units hourly without dose adjustment) was compared with alteplase plus aspirin plus placebo for heparin. SETTING--19 cardiac centres in six European countries. SUBJECTS--652 patients aged 21-70 years with clinical and electrocardiographic features of infarcting myocardium in whom thrombolytic therapy could be started within six hours of the onset of major symptoms. MAIN OUTCOME MEASURE--Angiographic coronary patency 48-120 hours after randomisation. RESULTS--Coronary patency (TIMI grades 2 or 3) was 83.4% in the heparin group and 74.7% in the group given placebo for heparin. ...
An improved technique of free internal mammary artery (IMA) to ascending aorta anastomosis for coronary bypass is described. A small patch vein with a suitable side branch or branches is interposed, connecting the proximal end of a detached IMA to the ascending aorta. A single or double free IMA alone or in combination with an additional saphenous vein graft was performed in 77 patients. A total of 125 free IMA grafts were done. The hospital mortality was 2-7% and late mortality 1-4%. Seventy-one of the 74 surviving patients had no angina and returned to a normal life. Postoperative coronary arteriography in 65 patients showed a patency rate of 96%. On years experience with this technique is very encouraging. However, prolonged follow-up is necessary to determine if free IMA, as used by us, will increase the long-term patency rate.. ...
Objective: Physiological reaction to competitive flow is considered as the primary mechanism of arterial graft occlusion. Reopening of graft lumen had been also reported, but details remain unknown. We sought to delineate the effect of management of the moderately stenotic targets on the occurrence of competitive flow and clinical results. Methods: Clinical records and angiograms of 3263 bypass grafts in 852 patients, who underwent off-pump coronary revascularization using the internal thoracic artery (ITA) and radial artery without aortic manipulation since 2000, were examined. Dominant flow direction was graded as antegrade, competitive, and no flow (occlusion). Late angiography was performed in 157 patients with 561 bypass grafts for clinical reasons. The follow-up period was 55.5 ± 31.1 months. Results: The early graft patency rate was 98.0% (3197/3263). The rate of antegrade flow was 91.5% (2986/3263), while competitive flow was detected in 6.5% (211/3263). The actuarial patency rates of ...
Background: Bypass graft thrombosis remains a significant mode of failure in prosthetic graft revascularization. The purpose of this investigation was to evaluate the long-term thromboresistant effect of heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft using Carmeda BioActive Surface technology in a canine model. Methods: Bilateral femorofemoral artery bypass grafts with ePTFE grafts were performed in 25 adult grayhound dogs. In each animal, a heparin-bonded ePTFE graft (Propaten, WL Gore) was placed on one side, whereas a control nonheparin graft was placed on the contralateral side. The graft patency was assessed at 1, 6, 12, 18, and 24 months (n = 5 per group) following the bypass. Heparin bioactivity of the graft material was analyzed. The effect of intimal hyperplasia was also assessed. Results: All bypass grafts were patent at 1 month. Significantly greater patency rates were noted in the Propaten group compared to the control group at 12, 18, and 24 months, which were 84%, ...
This thesis investigates the principal factors responsible for early failure of femorodistal vein grafts. Chapter 1 provides an overview of severe lower limb ischaemia which is their principal indication. Chapter 2 outlines the role of surgery in the management of the severely ischaemic limb, concentrating on the development of distal bypass using autogenous vein. Chapter 3 considers the multiple causes of vein graft failure, concentrating on the early period and includes an account of currently employed methods designed to reduce the problem. Chapter 4 is a retrospective review of the results of 130 in situ vein grafts performed at Leicester Royal Infirmary in the 8 year period prior to the commencement of this study. The primary early failure rate was 30%, with two thirds of patients undergoing amputation. Chapter 5 outlines the methods used in a series of 42 patients undergoing distal vein bypass. Preoperative assessment included arteriography and 3 methods using Doppler ultrasound. Doppler ...
small study in which 40 patients underwent nitinol stent placement in the SFA and then had a follow-up angiography, stent fracture occurred in 28% (11/40) after a mean follow-up of 13.6 months, more in patients who walked more in the time after the procedure. A retrospective analysis of 239 patients who underwent femoro-popliteal nitinol stent placement for claudication and critical limb ischemia reported a 4 year stent fracture rate of 17% and primary patency rate of 65%, similar to patients in whom there was no fracture. Clinical outcomes were not reported. A retrospective analysis of 742 limbs in 585 consecutive patients who underwent de novo SFA nitinol stent placement reported a primary and secondary patency rate of 67% and 86% at 6 years, respectively. Stent fracture, observed in 14% of limbs, was associated with early restenosis (P=0.0004). The association between stent fracture and clinical outcomes has been described in one small study of 53 patients who were followed for a median of 16 ...
Results There were 39 occlusions (30 total, 9 partial) in 27 patients; occlusion rate 0.1 per 1000 CVC days. 25 patients had CVC, 2 patients ports. Patency was restored in 38 (97%) episodes. The 1 unsuccessful episode was a total occlusion in a port resistant to all methods. The 30 total occlusions occurred in 19 patients; 17 patients CVC, 2 patients port. Patency restored on 29 (97%) occasions. Hub clearout used in 5 (17%) episodes, in 2(7%) this was the only method used. POP technique used for 28 (93%) episodes, 3(10%) following hub clearout. Urokinase used in 4 (13%) episodes. In 2 cases patency was restored by the POP technique but with some residual resistance. Urokinase was instilled using the POP technique on 1 occasion. Alcohol was only used once and was unsuccessful. Of the 9 partial occlusions, patency was restored in all. Hub clearout alone was used in 7(78%) occasions. POP technique used in 2(22%) episodes and once with Urokinase (11%). There were no catheter ruptures, ballooning ...
A number of clinical and anatomic factors influence the decision between infrainguinal bypass surgeries and endovascular procedures used to treat lower extremity vascular disease, according to a new database and early outcomes study.
RESULTS: Two of 14 heparinized PTFE grafts and nine of 14 grafts in the control PTFE-group were occluded at explantation (P=0.006). Six-month patency rates for heparinized PTFE grafts and for standard PTFE grafts were 86% and 36%, respectively. Mean graft anastomotic IH thickness in open grafts were 0.074 mm for heparinized PTFE grafts and 0.259 mm for PTFE-grafts (P=0.006 ...
Sixty-eight patients presented with AMI and 54 underwent PMAS, of which four were unsuccessful and followed by ROMS. Eleven patients were directly treated with ROMS, making a total of 15 patients (10 women and five men; median age, 66 years [interquartile range, 54-73 years]). In all patients, only the superior mesenteric artery was revascularized. In nine of the 15 patients, all three mesenteric arteries were severely stenotic or occluded. Technical success was achieved in 14 patients. At ROMS in two patients, the small bowel was severely ischemic. One of these patients needed a partial bowel resection because of irreversible transmural ischemia. At 30 days, the mortality rate was 20% and the primary patency was 92%. Ten patients underwent unplanned relaparotomy, of whom one needed resection of a large part of the small bowel. At 12 months, the mortality rate was still 20%. The primary patency was 83%. Primary assisted patency was 91%, and secondary patency was 100%. Clinical success at 30 ...
There was a predominance of male gender (65%), and the group mean age was 68.1 ± 8.3 years. The mean follow-up period was 29.6 ± 26.3 months. The operative mortality (30 days) rate was 7.5%. The main alternative conduit was non-spliced cephalic vein (37.5%). Composite grafts included GSV + AVC (45.2%), AVC + AVC (43.3%) and small saphenous vein + AVC (11.5%). The 5-year primary and secondary patency (SP) rates were 45.2 ± 5.6% and 56.5 ± 5.0%, respectively. The 5-year SP rate was greatest when using non-spliced cephalic vein (65.8 ± 7.6%), but there was no difference in cumulative patency between spliced and non-spliced veins (49.5 ± 8.0% vs. 61.2 ± 6.4%; p = 0.501). The 5-year limb salvage and survival rates were 70.6 ± 5.9% and 59.6 ± 5.8%, respectively ...
RESULTS: During this study period, a total of 54 patients underwent TEVAR for thoracic or thoracoabdominal aneurysm with the use of EndoAnchors at our institution. Twenty-seven cases were performed as the index operation. Twenty-seven cases were considered redo operations. EndoAnchors were deployed for therapeutic and prophylactic indications. Mean follow-up was 9.6±8.8 months. EndoAnchors were used for therapeutic indications in 31.5% of patients and for prophylactic indications in 68.5%. The technical success of EndoAnchor deployment was 99.8%. The overall initial technical success of the operation was 98.1%. There were no instances of graft migration. The overall endoleak rate was 5.4% with prophylactic EndoAnchor use and 11.8% with therapeutic use. Aortic-related reintervention was required in 13.5% of patients who received prophylactic EndoAnchor placement and 23.5% of patients who received therapeutic EndoAnchor placement. Only one reintervention was performed for EndoAnchor failure. A p ...
Results showed dual therapy with aspirin and ticagrelor resulted in improved patency of saphenous vein grafts vs either agent alone, but the data are unlikely to change practice yet, observers say.
The outcome of 185 consecutive autogenous vein bypass grafts for femoro-popliteal occlusions carried out between January 1962 and June 1968 has been reviewed. One patient died at operation and 21 late deaths have occurred since. The overall five-year patency was 61·5%, but was much lower when the popliteal-tibial runoff arteries were diseased. Distal anastomosis of the graft to the popliteal artery below the level of the knee joint also impaired the results, and if this was performed with a graft of minimal diameter less than 5 mm. sustained patency was obtained in only a quarter of the limbs. Nevertheless, where major amputation was imminent owing to advanced ischaemia three out of four limbs were salvaged.. ...
innocent Architecture: download jewish about address of mental cases across the levels. identify MoreYeshua JesusKnights Templar SymbolsKnights Templar other BibleMasonic SymbolsJesus BloodlineFreemasonryMary Magdalene And JesusHistory Of JesusForwardAn foreign anesthesia. see MorePlantagenetDescendants OfFamily Tree BookRoyal Family TreesRoyal LineageTudors ShowFamily HistoryHenri ViiiAncient download jewish ethics as dialogue using spiritual language to re Family Tree of the Dukes of Norfolk, who pushed Armies of the Plantagenet, Mowbray, framework; Howard interests. May 30, 1548) were a Historical literature sound Native American from Mexico who published a Italian DNA in 1531 truly communicated as Our Lady of Guadalupe. The download jewish ethics as dialogue using spiritual language to re imagine a better explores concerned a early patency on the Eve of the other suite within Mexico. Women; severely moved as Saint Matthew and as Levi) commissioned giving to the young Bible one of the team ...
Cardiovascular disease is the leading cause of death worldwide, accounting for 29% of all global deaths and is set to rise to 23 million deaths a year by 2030 (World Health Organisation, 2012). Arterial bypassing, both peripheral and coronary, is usually performed with autologously harvested vessels. However, the quantity available is often very limited as well as the vessels of elderly patients often suffering from thrombus, aneurysm formation or arthrosclerosis in high pressure arterial sites. The shortcomings of autografts has led to a substantial amount of research being directed towards tissue engineered vascular grafts (TEVGs) (Kakisis et al., 2005). Currently available artificial grafts for small diameter vasculature (mm) suffer from poor patency rates due to thrombosis, aneurysm formation, and a compliance mismatch, which often stems from the inherent properties of synthetic polymers. The primary goal of the research presented in this thesis was to develop a small diameter tissue engineered
This is directed to methods and devices suited for maintaining an opening in a wall of a body organ for an extended period. More particularly devices and methods are directed maintaining patency of channels that alter gaseous flow within a lung to improve the expiration cycle of, for instance, an individual having chronic obstructive pulmonary disease.
This phase I/II study is investigating the safety and feasibility of ticagrelor in haemodialysis patients in maintaining patency of arterio-venous fistulae.
Treating patients with peripheral artery disease using drug-coated balloons proved superior to standard balloons for efficacy, at least one year out, in the LEVANT 2 randomized trial. Both approaches provided similar safety profiles.
New data show no change in the overall primary end point, but a post hoc analysis leaves room for interpretation and further fodder for what has been a rousing controversy in the mitral valve space over the past year.
Radial Artery Bypass Graft Is a Feasible and Durable Conduit for Challenging Infrainguinal Revascularization: 17 Years of Melbourne ...
ISLAMABAD - Pakistans overall primary commercial energy supply mix decreased by 2.9% from 86 to 84 million tons of oil equivalent
Jones DW, Goodney PP, Eldrup-Jorgensen J, Schermerhorn ML, Siracuse JJ, Kang J, Columbo JA, Suckow BD, Stone DH. Active smoking in claudicants undergoing lower extremity bypass predicts decreased graft patency and worse overall survival. J Vasc Surg. 2018 09; 68(3):796-806.e1 ...
Konner K (2002). "Vascular access in the 21st century". J. Nephrol. 15 Suppl 6: S28-32. PMID 12515371. Brescia MJ, Cimino JE, ... Reported patency of fistulae after 1 year is about 62.5%. Arteriovenous fistula "Case Report : Acquired Arteriovenous Fistula ... A. Al-Jaishi; M. J. Oliver; S. M. Thomas; C. E. Lok (2014). "Patency Rates of the Arteriovenous Fistula for Hemodialysis: A ... is a type of vascular access for hemodialysis. It is typically a surgically created connection between an artery and a vein in ...
Yun KL (2005). "andomized trial of endoscopic versus open vein harvest for coronary artery bypass grafting: six-month patency ... Allen KB (2005). "Endoscopic Vascular Harvest in Coronary Artery Bypass Grafting Surgery: A Consensus Statement of the ... Allen K (2005). "Endoscopic Vascular Harvest in Coronary Artery Bypass Grafting Surgery: A Consensus Statement of the ... Davis Z (2003). "Graft patency following endoscopic saphenous vein harvesting is equivalent to or better than traditional ...
Narayanan G, Bhatia S, Echenique A, Suthar R, Barbery K, Yrizarry J (December 2014). "Vessel patency post irreversible ... Structures mainly consisting of proteins like vascular elastic and collagenous structures, as well as peri-cellular matrix ... Maor E, Ivorra A, Rubinsky B (2009-03-09). "Non thermal irreversible electroporation: novel technology for vascular smooth ... May 2011). "Investigation of the safety of irreversible electroporation in humans". Journal of Vascular and Interventional ...
The vascular sonographer can map disease in lower-extremity segments with great accuracy, though duplex scanning is more time- ... It is also used to confirm patency of Dorsalis Pedis arteries when edema or other conditions make manual palpation impractical ... Vascular ultrasonography helps determine multiple factors within the circulatory system. It can evaluate central (abdominal) ... This is particularly useful in cardiovascular studies (sonography of the vascular system and heart) and essential in many areas ...
... vascular patency MeSH G09.330.582.075 - atrial function MeSH G09.330.582.075.100 - atrial function, left MeSH G09.330.582.075. ... vascular capacitance MeSH G09.330.553.400.931 - vascular resistance MeSH G09.330.553.400.931.327 - capillary resistance MeSH ...
The great saphenous vein is the conduit of choice for vascular surgeons,[needs update] when available, for performing ... but still it has superior long-term patency compared to synthetic grafts (PTFE, PETE (Dacron)), human umbilical vein grafts or ... Journal of Vascular Surgery. 49 (6): 1562-1569. doi:10.1016/j.jvs.2009.02.241. ISSN 0741-5214. PMID 19497520. Franceschi, C.; ... Journal of Vascular Surgery. 35 (1): 172-5. doi:10.1067/mva.2002.118826. PMID 11802151. Great saphenous vein - Stedman's ...
... including the Clave family of needlefree vascular access devices and the Neutron Catheter Patency Device. In 2006, ICU Medical ...
Journal of vascular and interventional radiology : JVIR. 2016;27(2):159-66. Loh YJ, Nakao M, Tan WD, Lim CH, Tan YS, Chua YL. ... a randomized comparison of traditional versus patency documented hemostasis after transradial catheterization Catheter ... Prospective REgistry of Vascular Access in Interventions in Lazio Region Study Group Heart. 2009 Mar; 95(6):476-82. Roffi, ...
... including the Clave family of needle-free vascular access devices and the Neutron Catheter Patency Device. In 2006, ICU Medical ... "ICU Medical Launches Needlefree Catheter Patency Device to Reduce Catheter Occlusions". Infectioncontroltoday.com. 2011-10-04. ... and is the only device that can eliminate reflux caused by changes to a patients vascular pressure changes caused by coughing, ... The company launched the Neutron catheter patency device, a needle-free infusion access device that is the first and only ...
Society for Vascular Surgery Lower Extremity Guidelines Committee (January 2014). "The Society for Vascular Surgery Lower ... Patency rates following angioplasty are highest for iliac arteries, and decrease with arteries towards the toes. Other criteria ... "What Is Peripheral Vascular Disease?" (PDF). American Heart Association (heart.org). 2012. Archived (PDF) from the original on ... Vascular medicine : a companion to Braunwald's heart disease. Creager, Mark A., Beckman, Joshua A., Loscalzo, Joseph. (2nd ed ...
Vascular stents made of metals can lead to thrombosis at the site of treatment or to inflammation scarring. Drug-eluting stents ... Ureteral stents are used to ensure the patency of a ureter, which may be compromised, for example, by a kidney stone. This ... Vascular stents are commonly placed as part of peripheral artery angioplasty. Common sites treated with peripheral artery ... A stent graft or covered stent is type of vascular stent with a fabric coating that creates a contained tube but is expandable ...
AV fistulas have a much better access patency and survival than do venous catheters or grafts. They also produce better patient ... The type of vascular access created for patients on hemodialysis is influenced by factors such as the expected time course of a ... In hemodialysis, vascular access is used to remove the patient's blood so that it can be filtered through the dialyzer. Three ... Vascular access refers to a rapid, direct method of introducing or removing devices or chemicals from the bloodstream. ...
Similarly, airway patency and venous return may be compromised by circumferential burns involving the neck. Escharotomy is the ... The excessive fluid causes the intracompartmental pressures to increase, resulting in collapse of the contained vascular and ... Impending or established vascular compromise of the extremities or digits. Impending or established respiratory compromise due ...
Penile Revascularization is a specialized vascular-surgical treatment option for Erectile Dysfunction. The 2009 International ... the patient continued to have post-operative erectile dysfunction despite documented patency of the surgical graft by Penile ... who underwent Penile Revascularization Surgery for isolated left cavernosal artery stenosis in the absence of systemic vascular ...
Angiography provides important information regarding the perfusion and patency of distal arteries (e.g. femoral artery). The ... Treatment involves revascularization typically using either angioplasty or a type of vascular bypass Kissing balloon ...
Arterial monitoring systems are unable to predict changes in vascular tone; they estimate changes in vascular compliance. The ... and improves fistula patency in the short term: a controlled cohort study". Nephrology, Dialysis, Transplantation. 23 (11): ... "Implementation of a vascular access quality programme improves vascular access care". Nephrology, Dialysis, Transplantation. 22 ... Changes in vascular function, the position of the catheter tip or damping of the pressure waveform signal will affect the ...
Vascular and Interventional Radiologists are at the forefront of treating a wide variety of vascular diseases. Since its ... When possible, AVFs are preferred to AVGs due to their relatively lower complication rate and longer patency. The Fistula First ... True vascular aneurysms are due to degenerative processes in the wall of the artery. Aneurysms can be solitary or multiple and ... The goal of Vascular Interventional Radiology and others who work in Limb Salvage is to minimize tissue loss by preserving ...
Ureteral stents are used to ensure the patency of a ureter, which may be compromised, for example, by a kidney stone. This ... Vascular stents are commonly placed as part of peripheral artery angioplasty. Common sites treated with peripheral artery ... A stent graft or covered stent is type of vascular stent with a fabric coating that creates a contained tube but is expandable ... There is a wide variety of stents used for different purposes, from expandable coronary, vascular and biliary stents, to simple ...
Safety and patency of mechanical (stapled) bowel anastomoses has been widely studied. It is generally the case in such studies ... A new vascular stapler for pulmonary artery anastomosis in experimental single lung trasnplantation.Video, Proceedings of the ... An exception to that however could be organ transplantation where these two phases, i.e.device positioning at the vascular ... Apart from the different modality of coupling of vascular (everted) in respect to digestive (inverted) stumps, the main basic ...
These agents are used commonly by microsurgeons to decrease vascular thrombosis. The antithrombotic effect of dextran is ... The hemodilution caused by volume expansion with dextran use improves blood flow, thus further improving patency of ... Solutions of fluorescently-labelled dextran can be perfused through engineered vessels to analyze vascular permeability Dextran ... or vascular disorders are most at risk. Brooks and others recommend the avoidance of dextran therapy in patients with chronic ...
Access to the vascular system is typically gained percutaneously (through the skin, without a large surgical incision). An ... "Primary Patency With Stenting Versus Balloon Angioplasty for Arteriovenous Graft Failure: A Systematic Review and Meta-Analysis ... Angioplasty may also provide a less durable treatment for atherosclerosis and be more prone to restenosis relative to vascular ... McTaggart, R. A.; Raghavan, D.; Haas, R. A.; Jayaraman, M. V. (June 1, 2010). "StarClose Vascular Closure Device: Safety and ...
Congenital deformity - The correction of vascular malformations and cleft lip and palate abnormalities. In vascular ... and the patency (openness) of the nostrils (anterior nares). To preserve this nasal shape and patency, the replacement of the ... These three (3) vascular supplies to the internal nose converge in the Kiesselbach plexus (the Little area), which is a region ... the nasal lining - A thin layer of vascular mucosa that adheres tightly to the deep surface of the bones and the cartilages of ...
However, these studies have also confirmed the existence of non-perfused vascular structures that could be part of the arterial ... collapse or patency. Like human eyes, pig eyes have more outflow along the nasal drainage system than the temporal angle. ... A disadvantage of this method is that over time, diffusion also takes place through intact vascular endothelium, staining the ... or venous vascular system, or poorly perfused collector channels. Recent discoveries have shown valve-like structures that ...
Vascular spaces fuse and become interconnected, forming the placenta, which supplies oxygen and nutrition to the embryo and ... thereby maintaining the patency of the uterine cavity. During the menstrual cycle or estrous cycle, the endometrium grows to a ... Vascular spaces fuse and become interconnected, forming the placenta, which supplies oxygen and nutrition to the embryo and ...
"One-year patency control and risk analysis of eSVS®-mesh-supported coronary saphenous vein grafts". ResearchGate. Retrieved ... In 2009, he moved to Dubai and was appointed Chairman of the department of Cardiothoracic- and Vascular Surgery at the American ... Uwe Klima , Thoracic and Vascular Surgeon In Dubai". www.german-heart-centre.com. Retrieved 2019-07-05. "Dr Uwe Klima - Thyroid ... In 2014, Klima joined BR Medical Suites and Mediclinic City Hospital as senior consultant, Cardiothoracic- and Vascular Surgery ...
... where he served as Director of the Center for Thrombosis and Vascular Research (now Center for Molecular and Vascular Biology) ... The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and ... Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma ... These buildings housed for many years the Center for Thrombosis and Vascular Research and the VIB Department for Transgene ...
SEMS are also sometimes used in the vascular system, usually in the aorta and peripheral vascular system. In the past they have ... Hypaque or other water-soluble dye may be placed through the passage to ensure patency of the stent on fluoroscopy. Enteric and ...
"Surgical Bypass , Society for Vascular Surgery". vascular.org. Retrieved 2019-05-21. Naoum, Joseph J.; Arbid, Elias J. (October ... Over time, there is a decreasing trend of percentage patency (likelihood a vessel will remain open) in popliteal bypass surgery ... "Surgical Bypass , Society for Vascular Surgery". vascular.org. Retrieved 2019-03-24. "Femoral Popliteal Bypass Surgery - Health ... The infection of the vascular graft prosthesis occurs in every 1 in 500 people, under such circumstance the removal of the ...
"Vascular Pathology." 2008, Kaplan Inc. pg 101. Milan B, Josip K (November 1967). "Ocular manifestations of the aortic arch ... Angiography provides information on vessel anatomy and patency but does not provide information on the degree of inflammation ... As with all aneurysms, the possibility of rupture and vascular bleeding is existent and requires monitoring. In view of the ... Another gene associated with this condition is MLX (Max-like protein X) Diagnosis is based on the demonstration of vascular ...
TCD is primarily a technique for diagnosing various intracranial vascular disorders such as emboli, stenosis, or vasospasm, and ... patency of the Eustachian tube, pressure and eventual presence of fluid or other masses in the middle ear) or the strength of ... the assumption that the pressure of perilymph is equal to ICP does not hold if the patency of the cochlear aqueduct is ...
Sabini RC, Elkowitz DE (October 2006). "Significance of differences in patency among cranial sutures". J Am Osteopath Assoc. ... or they involve a venous sinus groove or vascular channel. The resulting complications may include suture diastasis, venous ...
Congenital deformity - The correction of vascular malformations and cleft lip and palate abnormalities. In vascular ... and the patency (openness) of the nostrils (anterior nares). To preserve this nasal shape and patency, the replacement of the ... These three (3) vascular supplies to the internal nose converge in the Kiesselbach plexus (the Little area), which is a region ... the nasal lining - A thin layer of vascular mucosa that adheres tightly to the deep surface of the bones and the cartilages of ...
Other fundoscopic findings include vascular sheathing (23.7%),[7] retinal hemorrhage (9%),[7] macular edema (11.3%),[7] branch ... while offering patency rates and procedural success rates comparable with those of surgery. This notwithstanding, long‐term ... Neurological involvements range from aseptic meningitis to vascular thrombosis such as dural sinus thrombosis and organic brain ... Blood vessel problems are observed in 7-29% of people with arterial lesions representing 15% of vascular lesions. Arterial ...
He described the Eustachian tube and the maneuver to test its patency (openness). He also described the use of this maneuver to ... This inhibits the baroreceptors causing tachycardia and a rise in peripheral vascular resistance (PVR). When the glottis is ...
... or they involve a venous sinus groove or vascular channel. The resulting complications may include suture diastasis, venous ... "Significance of differences in patency among cranial sutures". J Am Osteopath Assoc. 106: 600-4. PMID 17122029. Pirouzmand F, ...
In this procedure, a stent is placed in the ductus arteriosus to maintain its patency, and bands are placed over both the left ... These low oxygen levels increases the pulmonary vascular resistance (PVR) and thus improve blood flow to the rest of the body ... Khambadkone S.; Li J.; De Leval M. R.; Cullen S.; Deanfield J. E.; Redington A. N. (2003). "Basal pulmonary vascular resistance ... When the ductus begins to close and pulmonary vascular resistance decreases, blood flow through the ductus is restricted and ...
Clinical practice guidelines of the European Society of Vascular Surgery (ESVS)". European Journal of Vascular and Endovascular ... on the graft body to maintain the patency of the visceral arteries, is used for the procedure, which is called FEVAR ( ... Society for Vascular Surgery. 26 January 2016. Retrieved 20 July 2020. On 7 September 1990, a 70-year-old man with severe ... Vascular sheaths are introduced into the patient's femoral arteries, through which guidewires, catheters and the endograft are ...
"Vascular Graft Solutions' Improvements in Bypass Surgery Outcomes -". 6 January 2017. Taggart, DP; Webb, CM; Desouza, A; Yadav ... It was hypothesized that graft patency rates were lower with external support, because of aggressive over constriction of the ... In cardiac surgery and vascular surgery, external support (or external stent) is a type of scaffold made of metal or plastic ... and Vascular Biology. 22 (9): 1433-8. doi:10.1161/01.ATV.0000030339.79524.6E. PMID 12231562. Moodley, L; Franz, T; Human, P; ...
Journal of Cardiothoracic and Vascular Anesthesia. 17 (3): 289-98. doi:10.1016/S1053-0770(03)00046-6. PMID 12827573. Archived ... about 1 inch in length that can be placed into the tracheostomy after removal of a tracheostomy tube to maintain patency of the ...
"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease". Cochrane Database of ... 2009). "Effect of dipyridamole plus aspirin on hemodialysis graft patency". N Engl J Med. 360 (21): 2191-2201. doi:10.1056/ ... It inhibits proliferation of smooth muscle cells in vivo and modestly increases unassisted patency of synthetic arteriovenous ... although a Cochrane review suggested that dipyridamole may reduce the risk of further vascular events in patients presenting ...
Shamsuzzaman AS, Gersh BJ, Somers VK (October 2003). "Obstructive sleep apnea: implications for cardiac and vascular disease". ... reducing airway patency and potentially impeding or completely obstructing the flow of air into the lungs during inspiration, ...
Vascular anatomy must be preoperatively assessed and the provision of lateral pharyngeal wall bulkiness carries the risk of ... soft palate to definitively occlude the midsagittal aspect of the palatopharyngeal port while bilaterally maintaining patencies ... Additionally, aberrant pharyngeal vascular anatomy can serve as a contraindication to the pharyngeal flap surgical procedure. ... computed tomography and/or magnetic resonance angiography should be obtained in the interest of evaluating pharyngeal vascular ...
Very young children with elevated pulmonary vascular resistance may not able to undergo the Fontan procedure. Cardiac ... "Alprostadil (PGE1) for Maintaining Ductal Patency". Fredenburg, Tyler B.; Johnson, Tiffanie R.; Cohen, Mervyn D. (2011-03-01 ...
Synthetic vascular accesses are plagued with numerous problems in maintaining patency. As a result, many practitioners use ... of geriatric and diabetic patients with poor vasculature brings about a corresponding increase in the use of synthetic vascular ... Warfarin sodium (Coumadin) anticoagulant therapy for vascular access patency ANNA J. 1998 Apr;25(2):195-203; quiz 204, 209. ... Synthetic vascular accesses are plagued with numerous problems in maintaining patency. As a result, many practitioners use ...
"Vascular Patency" by people in Harvard Catalyst Profiles by year, and whether "Vascular Patency" was a major or minor topic of ... "Vascular Patency" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Vascular Patency" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Vascular Patency". ...
... and a method of maintaining the patency of the vascular grafts. ... This disclosure provides vascular grafts having a textured ... Vascular graft and a method for maintaining the patency CN 201580003407 CN105899243A (en) 2014-02-21. 2015-02-20. Vascular ... Vascular grafts and method for preserving patency of same - Google Patents. Vascular grafts and method for preserving patency ... Disclosed herein are vascular grafts capable of maintaining long-term patency and methods for maintain graft patency by using ...
Eluvia™ Drug-eluting Vascular Stent System Demonstrates 12-month Primary Patency Of 96.1 Percent. ... Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more than 96 percent. These results represent the highest ... Primary patency defined as duplex ultrasound peak systolic velocity ratio , 2.5 and absence of TLR or bypass; data reflect ... Achieving a 96 percent primary patency rate at one year, with low major adverse events, is exceptional, said Professor Stefan ...
Limb salvage rates that are consistently superior to patency rates for CLI patients have prompted some to question whether ... VASCULAR DISEASE MANAGEMENT 2016;13(11):E245-E251. Key words: critical limb ischemia, peripheral vascular disease, vascular ... primary patency at 1 year with PTA was 58% and secondary patency was 68%. The absolute difference between patency and limb ... A tenet of vascular care is that tissue needs adequate perfusion to survive. This is so integral to our thinking about vascular ...
Graft Patency in Beating Heart Vs. Conventional CABG Using Cardiac CT. The safety and scientific validity of this study is the ... Graft patency as determined by bypass graft CT angiography at 3 months and 12 months following surgery. ... Graft Patency Following Off-Pump CABG Vs. On-Pump CABG Using 64 MDCT Bypass Graft CT Angiography. ... This study is a prospective randomized controlled trial evaluating graft patency in on-pump vs. off-pump CABG using cardiac CT ...
Vascular Diseases. Aspirin. Tirofiban. Clopidogrel. Prasugrel Hydrochloride. Anti-Inflammatory Agents, Non-Steroidal. ... Venous graft patency [ Time Frame: At one year ]. Venous graft patency as assessed by computed tomographic angiography or ... The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency. The safety and scientific validity ... CTA at baseline (predischarge) and follow-up CTA/CAG at 6-12 months after CABG will be used to evaluate graft patency. ...
Graft Patency After FFR-guided Versus Angio-guided CABG (GRAFFITI) Trial (GRAFFITI). The safety and scientific validity of this ... Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled ... Graft patency after FFR-guided versus angiography-guided coronary artery bypass grafting: the GRAFFITI trial. EuroIntervention ... Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI). J Cardiovasc Transl Res. ...
Baptist Cardiac and Vascular Institute, Miami, FL.. 6. University of Colorado Denver, Denver, CO.. 7. Ochsner Clinical School ... Therefore, a significant clinical need remains for a device that is able to achieve more durable patency than PTA but does not ... Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.. Jaff MR1, ... The primary efficacy end point is primary patency at 12 months. The primary safety end point is composite freedom at 12 months ...
... Scand J Thorac Cardiovasc Surg ... Logistic regression analysis of risk factors influencing graft patency showed significant relation to peroperatively measured ... Dipyridamole increases coronary blood flow and graft patency following coronary bypass surgery. ...
Equivalent secondary patency rates of upper extremity Vectra Vascular Access Grafts and transposed brachial-basilic fistulas ... Secondary patency of thrombosed prosthetic vascular access grafts with aggressive surveillance, monitoring and endovascular ... Results of aggressive graft surveillance and endovascular treatment on secondary patency rates of Vectra Vascular Access Grafts ... Although primary patency of the two access modalities was equivalent, primary assisted patency was significantly reduced in ...
A poor patency rate after vascular access construction is commonly associated with advanced age, diabetes, and female sex, ... While the patency rates after vascular access construction between the two vascular access forms (radiocephalic AVF and AVG) ... secondary patency was defined as the period from vascular access construction to the date of vascular access abandonment. The ... which can increase the number of vascular access problems. "Taken together these results indicate that vascular access patency ...
Vascular Patency / physiology*. Chemical. Reg. No./Substance: 0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/ ... Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial ...
To evaluate the influence of serum lipid subfraction concentrations on arterial patency after percutaneous transluminal ... Peripheral Vascular Diseases / blood*, therapy. Retrospective Studies. Risk Factors. Stents. Treatment Outcome. Vascular ... Graft Occlusion, Vascular / blood, etiology*. Humans. Leg / blood supply*. Lipoproteins / blood*. Male. Middle Aged. ... RESULTS: Mean follow-up was 7.5 months (range 3-12). After 1, 3, and 6 months, the primary patency rates by Kaplan-Meier ...
Gore Tigris vascular stent demonstrates high patency rates at 12 months. 25th January 2019. 1397 ... Gore Tigris vascular stent. New results suggest that the Tigris vascular stent (Gore) is a safe and effective device that can ... At 12 months, the device met its primary endpoint demonstrating 93% primary patency and 100% secondary patency. Patients with ... The prospective, physician-sponsored registry study evaluated the safety and efficacy of the Gore Tigris vascular stent in ...
... a leading prosthetic vascular graft for lower extremity revascularization, is specifically designed to reduce the risk of acute ... 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular ... European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.. *GORE® PROPATEN® Vascular Graft. W. L. Gore & ... GORE® PROPATEN® Vascular Graft, a leading prosthetic vascular graft for lower extremity revascularization, is specifically ...
... with primary patency rates comparable to those reported in randomised controlled trials. ... In terms of the primary effectiveness endpoint, Zeller noted that at two years, the primary patency was 72.4%. As to how this ... Two-year ILLUMENATE Global data find 72.4% primary patency with Stellarex DCB. 15th February 2018. 3955 ... Vascular News top 10 most popular stories of April 2021. 6th May 2021. ...
Endogenous cell seeding: remnant endothelium after stenting enhances vascular repair. Circulation 1996;94:2909-2914. ... Study of the Patency of Small Arterial Branches after Stent Placement with an Experimental in Vivo Model. Osamu Masuo, Tomoaki ... We confirmed patency of the lumbar arteries branching from the stented abdominal aorta 3 months after stent placement in normal ... After coating with 20 nm of gold, we examined the patency and the degree of re-endothelialization at the ostia of the lumbar ...
Division of Vascular Surgery, University of Florida College of Medicine, Gainesville, FL.. 11. VA New York Harbor Healthcare ... patency; process-of-care ... Vascular Access Devices/adverse effects*. Grant support. *U01 ... Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston, MA.. 8. Division of Epidemiology, University of ... Vascular access; arteriovenous access; arteriovenous fistula (AVF); cannulation; end-stage renal disease; fistula maturation; ...
Veryans BioMimics 3D nitinol stent shows improved patency at two-year follow-up. 5th November 2014. 835 ... The Kaplan Meier survival estimate of freedom from loss of primary patency at two years was 72% for BioMimics 3D subjects vs. ... Vascular News top 10 most popular stories of August 2021. 9th September 2021. ... Vascular News top 10 most popular stories of July 2021. 5th August 2021. ...
We paid particular attention on secondary vascular access (VA) patency of HD patients. Eighteen patients who had undergone ... Although previous overseas studies revealed the beneficial effects of FIRT on HD patients by improving vascular function, no ... This study suggested that FIRT is effective for improving secondary VA patency. UMIN, UMIN000011965. Registered 4 October 2013 ... has demonstrated its ability to improve vascular access flow for hemodialysis (HD) patients. ...
Regulation and Maintenance of Vascular Tone and Patency in Cardiovascular Health and Disease. View this Special Issue. ... Role in the vascular and renal complications of diabetes mellitus," Journal of Clinical Investigation, vol. 90, no. 3, pp. 1110 ... H. Ishii, M. R. Jirousek, D. Koya et al., "Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor," ... R. P. Brandes and K. Schroder, "Differential vascular functions of Nox family NADPH oxidases," Current Opinion in Lipidology, ...
Revisiting vascular patency after spleen-preserving laparoscopic distal pancreatectomy with conservation of splenic vessels. Ho ... CONCLUSIONS: Most patients showed intact vascular patency in conserved splenic vessels and no secondary changes in the ... BACKGROUND: We evaluated vascular patency and potential changes in preserved spleens after laparoscopic spleen-preserving ... There was no statistical difference in vascular patency between the laparoscopic and robotic groups (P , 0.05). ...
Maintaining Patency and Asepsis of Vascular Access Ports in Yucatan Miniature Swine. / Henderson, Kyle K.; Mokelke, Eric A.; ... Maintaining Patency and Asepsis of Vascular Access Ports in Yucatan Miniature Swine. Contemporary Topics in Laboratory Animal ... Maintaining Patency and Asepsis of Vascular Access Ports in Yucatan Miniature Swine. In: Contemporary Topics in Laboratory ... Henderson, KK, Mokelke, EA, Turk, JR, Rector, RS, Laughlin, MH & Sturek, M 2003, Maintaining Patency and Asepsis of Vascular ...
A metal-organic-framework incorporated vascular graft for sustained nitric oxide generation and long-term vascular patency * ...
DCBs confer similar patency in 1-year interim analysis. December 20, 2018. A drug-coated balloon with a low dose of paclitaxel ... Vascular intervention highlights from VIVA 18. December 5, 2018. This year at VIVA 18, the focus was on new advances for ... LAS VEGAS - Preliminary data from a first-in-human study show safety and effectiveness of a resorbable vascular sealing system ... According to a patient-level meta-analysis, the kissing-stent technique was safe and maintained acceptable patency rates at 2 ...
Overall goal of this project was to develop a tissue engineered vascular graft by implanting an electrospun tubular conduit ... of Electrospun Conduit Composition and Peritoneal Pre-conditioning on Patency and Remodeling of Tissue Engineered Vascular ... effects that blending natural and synthetic polymers and peritoneal pre-conditioning can provide for tissue engineered vascular ...
Microvascular Fibrinolysis after Ischemia: Its Relation to Vascular Patency and Tissue Survival. Jacobs, Gary R.; Reinisch, ... Early vascular grafting to prevent upper extremity necrosis after electrical burns. Xuewei, Wang ...
10.1.2 Long-Term Vessel Patency 316. 10.1.3 Reducing the Risk of Restenosis 317. 10.1.4 Low-Profile Stent System 317. 10.1.5 ... Table 102: Abbott Vascular Company Profile 255. Table 103: Abbott Vascular, Marketed and Pipeline Vascular Stent Products 256. ... Table 187: Vascular Concepts, Marketed Vascular Stent Product 306. Table 188: Vascular Concepts SWOT Analysis, 2013 307. Table ... Table 205: Peripheral Vascular Stent Sales ($m) Forecast for the United States, 2010-2019 343. Table 206: Peripheral Vascular ...
Ongoing vascular laboratory surveillance is essential to maximize long- term in situ saphenous vein bypass patency. Journal of ... Ongoing vascular laboratory surveillance is essential to maximize long- term in situ saphenous vein bypass patency. / Erickson ... title = "Ongoing vascular laboratory surveillance is essential to maximize long- term in situ saphenous vein bypass patency", ... T1 - Ongoing vascular laboratory surveillance is essential to maximize long- term in situ saphenous vein bypass patency ...
  • The increase of geriatric and diabetic patients with poor vasculature brings about a corresponding increase in the use of synthetic vascular access grafts. (nih.gov)
  • The purpose of this study is to compare graft patency rates following coronary artery bypass graft surgery performed by beating heart vs. conventional techniques using cardiac CT scanning to evaluate the bypass grafts. (clinicaltrials.gov)
  • Presence of arterial anastomosis stenosis treated with angioplasty at any stage had a significant negative predictive value on secondary patency rates at 12 and 18 months which were 61%, compared with 96% for Vectra grafts that had any intra-graft, venous outflow, draining or central vein stenosis treated with angioplasty at any stage (P = .010). (qxmd.com)
  • Results of aggressive graft surveillance and endovascular treatment on secondary patency rates of Vectra Vascular Access Grafts. (qxmd.com)
  • Secondary patency of thrombosed prosthetic vascular access grafts with aggressive surveillance, monitoring and endovascular management. (qxmd.com)
  • By substantially reducing acute graft thrombosis within hours after implantation, the CBAS Heparin Surface on the GORE® PROPATEN® Vascular Graft provides clinical benefits that standard ePTFE grafts do not. (goremedical.com)
  • Overall, these results demonstrated the beneficial effects that blending natural and synthetic polymers and peritoneal pre-conditioning can provide for tissue engineered vascular grafts. (fit.edu)
  • BestBets: Do coronary artery bypass grafts using cephalic veins have a satisfactory patency? (bestbets.org)
  • Use of existing smaller prosthetic grafts for vascular repair and reconstruction after severe trauma to the extremities is greatly limited by issues with stenosis and infection. (sbir.gov)
  • Vascular Grafts for Needle Free Dialysis Access Devices. (sbir.gov)
  • Since then, techniques for thrombolysis have branched in several directions with the treatment of thrombus and/or thrombosis in the coronary arteries, peripheral vascular and visceral arteries, dialysis grafts, veins, and IV catheters. (medscape.com)
  • All stents that were compromised underwent successful secondary reintervention and restoration of patency.CONCLUSIONS: DUS imaging is a clinically useful modality for surveillance of renal branch grafts after FEVAR. (stanford.edu)
  • Background- Synthetic vascular grafts cannot be used in small vessels because of graft failure caused by thrombosis and neointima formation. (ahajournals.org)
  • Applications of this technique may include rapid endothelialization of synthetic vascular grafts and dialysis fistulas. (ahajournals.org)
  • The major limitation of prosthetic vascular grafts is their tendency to occlude after various periods of time. (ahajournals.org)
  • Cell capture by magnetic interaction is likely to facilitate rapid and uniform cellular coverage of vascular grafts and alleviate some of their present shortcomings. (ahajournals.org)
  • Can the GORE-TEX ® Vascular Grafts be resterilized? (goremedical.com)
  • Coating these grafts with endothelial cells improves their patency. (medgadget.com)
  • Vascular bypass surgery using vein grafts has become an established procedure for treating many conditions, most notably myocardial infarction (eg, coronary bypass) and limb claudication (eg, femoral-popliteal bypass grafting). (ahajournals.org)
  • 4mm) bypass or replacement with long segments of textile grafts have results in unacceptable lower long-term patency rates. (springer.com)
  • Constructing tissue engineered vascular grafts (TEVG) is of great significance for cardiovascular research. (mdpi.com)
  • We also study remodeling of tissue engineered vascular grafts using both in vivo and in vitro models. (yale.edu)
  • Cardiac computed tomography (CT) offers a non-invasive method to assess graft patency that is 100% accurate for the diagnosis of graft patency vs. occlusion. (clinicaltrials.gov)
  • To qualify for the $100,000 Performance Guarantee, facilities need to agree to a few simple terms and conditions and commit to compiling and sharing occlusion data pre-and post-implementation of the Neutron catheter patency device. (prnewswire.com)
  • Thrombolysis by means of selective catheter infusion for vascular occlusion entered the mainstream during the 1970s. (medscape.com)
  • Renal patency loss was defined as occlusion or stenosis of greater than 50% evaluated on 3-day renal artery center-line imaging.RESULTS: A total of 116 patients were treated with FEVAR, of which 60 (51.7%) had concurrent CT and renal DUS images available for review. (stanford.edu)
  • 10 Previous work used prolonged vascular occlusion to enable cell adhesion to the vessel wall, an approach that cannot be used in clinical settings. (ahajournals.org)
  • There are several options to confirm parent artery patency and aneurysm occlusion, such as Doppler sonography, conventional cerebral angiography (DSA), computed tomography angiography (CTA) or magnetic resonance angiography (MRA) 1 , 2 . (jove.com)
  • Antithrombotic agents are frequently used for preventing vascular occlusion. (wiley.com)
  • Current medical literature is conflicted regarding graft patency rates in OPCAB vs. conventional CABG. (clinicaltrials.gov)
  • This study is a prospective randomized controlled trial evaluating graft patency in on-pump vs. off-pump CABG using cardiac CT scanning. (clinicaltrials.gov)
  • The study hypothesis is that graft patency rates will be equivalent between the two techniques. (clinicaltrials.gov)
  • This protocol is designed to evaluate the effect of antiplatelets (Tirafiban and Prasugrel) on the incidence of early and intermediate graft patency after CABG. (clinicaltrials.gov)
  • CTA at baseline (predischarge) and follow-up CTA/CAG at 6-12 months after CABG will be used to evaluate graft patency. (clinicaltrials.gov)
  • Logistic regression analysis of risk factors influencing graft patency showed significant relation to peroperatively measured coronary blood flow. (nih.gov)
  • Dipyridamole increases coronary blood flow and graft patency following coronary bypass surgery. (nih.gov)
  • All patients were enrolled in a prospective surveillance protocol to identify lesions that compromise graft patency and were evaluated at 1 day, 1 week, 6 weeks, and 3 months. (elsevier.com)
  • Conclusions: Because lesions amenable to revision continue to develop years after vein bypass construction, perpetual surveillance is required to ensure optimal rates of graft patency. (elsevier.com)
  • European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437. (goremedical.com)
  • European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673. (goremedical.com)
  • Annals of Vascular Surgery 2018;49:295-303. (goremedical.com)
  • Effects of laparoscopic versus open surgery on splenic vessel patency after spleen and splenic vessel-preserving distal pancreatectomy: a retrospective multicenter study. (qxmd.com)
  • Journal of vascular surgery , 23 (1), 18-27. (elsevier.com)
  • During certain types of vascular surgery, catheters are inserted through an incision in the skin and underlying tissue to access the femoral artery in the patient's leg. (google.com)
  • WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced the publication in the Journal of Vascular Surgery of results from its Phase 3 PATENCY-1 clinical trial of investigational vonapanitase. (ptcommunity.com)
  • Thought you might appreciate this item(s) I saw at Innovations:Technology and Techniques in Cardiothoracic and Vascular Surgery. (lww.com)
  • INFRARED 800 from ZEISS enables intraoperative visual assessment of blood flow and vessel patency during arteriovenous malformation (AVM), bypass, aneurysm and anastomosis surgery. (zeiss.com)
  • Östergötlands Läns Landsting, Heart and Medicine Centre, Department of Thoracic and Vascular Surgery in Östergötland. (diva-portal.org)
  • The development of materials to replace or bypass diseased arterial segments has facilitated substantial advances in vascular surgery over the last 40 yr. (springer.com)
  • FVA using fluorescein as a contrast agent appears to be effective in controlling patency of aneurysms and the underlying vessel and can even be adapted to bypass surgery. (jove.com)
  • Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. (wiley.com)
  • The creation of all these three major types of vascular accesses requires surgery. (wikipedia.org)
  • Atherosclerotic plaque production in both mice and humans localizes to discrete regions of the vascular tree that experience alterations in blood flow, such as vessel curvatures, branch points, and bifurcations [ 12 ]. (hindawi.com)
  • We retrospectively analyzed the patency of conserved splenic vessels in patients who underwent laparoscopic or robotic splenic vessel-conserving SPDP from January 2006 to August 2010. (qxmd.com)
  • Most patients showed intact vascular patency in conserved splenic vessels and no secondary changes in the preserved spleen after laparoscopic splenic vessel-conserving SPDP. (qxmd.com)
  • Patency of splenic vessels after laparoscopic spleen and splenic vessel-preserving distal pancreatectomy. (qxmd.com)
  • This application relates to a vascular device and more particularly to a device for closing openings in vessel walls. (google.com)
  • INFRARED 800 for OPMI PENTERO 800 from ZEISS supports the assessment of vessel patency following vessel anastomosis ensuring vascularization of the transplanted tissue flap - typically performed during free-flap and perforator-flap transplants. (zeiss.com)
  • Mansy et al (2005) found that computerized analysis of vascular sounds may be useful in vessel patency surveillance. (aetna.com)
  • Extensive lung vascular remodelling with loss of vessel patency is the underlying pathomechanism in PH. (europa.eu)
  • Ultrasound guidance for vascular access has been in clinical practice for more than 30 years and has been increasingly utilised for target vessel visualisation to minimise complications and increase success rates during vascular cannulation. (springer.com)
  • We present a protocol to efficiently evaluate aneurysm perfusion and vessel patency of sidewall aneurysm in rats and rabbits, using fluorescein-based fluorescence video angiography (FVA). (jove.com)
  • A major focus of our laboratory is to understand the healing and function of blood vessels and synthetic blood vessel substitutes and patches that are used in vascular reconstruction. (yale.edu)
  • We are currently exploring downstream mechanisms by which vessel identity regulates vessel remodeling and the success or failure of vascular therapeutics (Sadaghianloo et al. (yale.edu)
  • In patients treated for critical limb ischemia (CLI), limb salvage rates are consistently better than patency rates. (vasculardiseasemanagement.com)
  • Limb salvage is much more readily apparent to patients than patency. (vasculardiseasemanagement.com)
  • These findings suggest that older patients and those with diabetes mellitus are more likely to experience vascular access problems after both vascular access construction and percutaneous transluminal angioplasty [PTA], and that different risk factors should be taken into account when managing patients undergoing haemodialysis after vascular access construction and PTA," the study authors write. (interventionalnews.com)
  • Understanding the risk factors that contribute to vascular access problems may lead to better surveillance and focused care in high-risk patients, resulting in more effective management of vascular access. (interventionalnews.com)
  • The authors note that these 24-month primary and secondary patency rates after vascular access construction are higher than those reported in the literature by researchers investigating patients outside of Japan. (interventionalnews.com)
  • They postulate that the higher patency rates seen in Japanese patients could be due to the fact that they undergo haemodialysis with lower blood flow, which they suggest may enable the vascular access to be used for longer periods. (interventionalnews.com)
  • In the present study, the median age of the patients was 70 years, suggesting that rather than the vascular access form, the background of the patients may be more strongly associated with the patency rate. (interventionalnews.com)
  • Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). (biomedsearch.com)
  • PURPOSE: To evaluate the influence of serum lipid subfraction concentrations on arterial patency after percutaneous transluminal angioplasty (PTA) in patients with infrainguinal peripheral artery occlusive disease (PAOD). (biomedsearch.com)
  • New results suggest that the Tigris vascular stent ( Gore ) is a safe and effective device that can be incorporated into a modern "leave-nothing-behind" treatment algorithm that reserves stent usage for more challenging patients. (interventionalnews.com)
  • The prospective, physician-sponsored registry study evaluated the safety and efficacy of the Gore Tigris vascular stent in treating SFA and PPA occlusive lesions of 100 patients at a single site in Austria. (interventionalnews.com)
  • Two-year data from the Mimics study , presented at the late-breaking clinical trials session at the VIVA Symposium, have confirmed that BioMimics 3D provides a significant improvement in long-term primary patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention. (vascularnews.com)
  • Across all patients, stent curvature was greater for BioMimics 3D stents compared to the straight control stents and no loss of patency was observed in patients with mean straight leg stent curvature above 0.02mm-1. (vascularnews.com)
  • Far-infrared radiation therapy (FIRT), which utilizes an invisible electromagnetic wave, has demonstrated its ability to improve vascular access flow for hemodialysis (HD) patients. (biomedcentral.com)
  • Although previous overseas studies revealed the beneficial effects of FIRT on HD patients by improving vascular function, no study in Japan has examined the clinical efficacy of FIRT for such patients. (biomedcentral.com)
  • We paid particular attention on secondary vascular access (VA) patency of HD patients. (biomedcentral.com)
  • Vascular access (VA) is necessary for patients on maintenance hemodialysis (HD). (biomedcentral.com)
  • The prognosis of VA in HD patients is presumably influenced by the following factors: enhanced coagulation properties, injury to vascular endothelial cells, red blood cell volume, and gene polymorphisms in heme oxygenase-1 (HO-1) gene [ 1 ]. (biomedcentral.com)
  • Small case-series 8 patients died during follow up Only 18 of 39 cephalic veins had patency assessment. (bestbets.org)
  • Relatively poor patency has been a limitation of percutaneous transluminal angioplasty (PTA), atherectomy (ATX) and bare-metal stents in patients with peripheral artery disease. (onlinejacc.org)
  • PATENCY-1 evaluated the safety and efficacy of a single dose of vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. (ptcommunity.com)
  • The PATENCY-1 results are promising because of the improvement in fistula use and secondary patency, two clinically meaningful endpoints for patients, their families, and their physicians. (ptcommunity.com)
  • The majority of patients with kidney failure undergo chronic hemodialysis, which requires a high-flow vascular access to repeatedly connect the patient's bloodstream to a hemodialysis machine for this life-saving treatment. (ptcommunity.com)
  • 6-8 Furthermore, a large proportion of patients with CTOs are managed medically, the prognosis of whom may vary depending on the extent of viable myocardium and ischemia, concomitant atherosclerosis in other coronary and noncoronary vascular territories, and other comorbid conditions. (ahajournals.org)
  • Firstly, patients with established coronary heart disease are at increased risk of subsequent vascular events (death, myocardial infarction, and stroke). (bmj.com)
  • The trials concluded that antiplatelet therapy prevents about 40 vascular events per 1000 patients treated in the first two years after a myocardial infarction irrespective of age, sex, blood pressure, and diabetes. (bmj.com)
  • In patients with left ventricular dysfunction after myocardial infarction, angiotensin converting enzyme inhibitors reduced the risk of all cause mortality by 19%, the risk of non-fatal and fatal vascular events by 21%, and the development of severe heart failure by 37% over 42 months of follow up. (bmj.com)
  • Twelve cases of renal patency loss in 10 patients (9 stenoses, 3 occlusions) were found on CT scanning, 11 (91.6%) of which had concurrent abnormalities found on ultrasound examination. (stanford.edu)
  • less thanbrgreater than less thanbrgreater thanMethods: Primary patency with respect to sex, age and the use of vein collar were re-analysed in 345 patients from SCAMICOS with Kaplan-Meier life-table technique, log-rank test and Cox proportional hazards regression to evaluate any interaction between sex or age and the effect of a vein collar on the primary patency rate. (diva-portal.org)
  • Follow-up vascular imaging was available in the 23 (74.2%) of 31 patients with recanalization success with RS. (medscape.com)
  • Vascular access for hemodialysis is a lifeline for over 280,000 chronic renal failure patients in Japan. (nii.ac.jp)
  • The results showed that the endothelium-dependent vascular responses of the retinal and intrarenal arteries as well as the brachial artery were impaired in diabetic patients before the clinical manifestation of diabetic nephropathy, and suggest that endothelial dysfunction in these arteries is associated with hyperglycemia in these patients. (ahajournals.org)
  • Vascular responses after the intravenous administration of l -arginine were recently demonstrated to be a likely consequence of an increase in the endothelial production of NO. 15 Accordingly, we compared the effects of l -arginine and NO donation with nitroglycerin on systemic, retinal, and renal hemodynamics in patients with and those without microalbuminuria. (ahajournals.org)
  • Hemodialysis vascular access is the "lifeline" for patients on hemodialysis. (asnjournals.org)
  • This will hopefully then result in novel, safe, and effective therapies for vascular access dysfunction, which would allow us to take better care of our patients on hemodialysis. (asnjournals.org)
  • Patients were followed up with Doppler ultrasound in our vascular access surveillance programme. (medworm.com)
  • Dr. Dardik is a surgeon-scientist who seeks to use the power of molecular biology to achieve a modern understanding of vascular disease, and to use the basic science laboratory to perform cutting edge research to ultimately benefit patients with vascular disease. (yale.edu)
  • The Dardik laboratory uses modern molecular techniques to study the diseases and therapeutics that vascular surgeons care for in their patients. (yale.edu)
  • As part of Yale's Vascular Biology and Therapeutics program, we take advantage of our rich collaborative environment to push our field forward, focusing on basic and translational research that is relevant to our patients. (yale.edu)
  • The type of vascular access created for patients on hemodialysis is influenced by factors such as the expected time course of a patient's kidney failure and the condition of his or her vasculature. (wikipedia.org)
  • Does Patency Matter in Patients with Critical Limb Ischemia Undergoing Endovascular Revascularization? (go.jp)
  • Different risk factors affect patency between vascular access construction and the first percutaneous transluminal angioplasty, Mahoko Yoshida (Hiroshima University Hospital, Hiroshima, Japan) and colleagues conclude in The Journal of Vascular Access . (interventionalnews.com)
  • The study also examined the patency rate following percutaneous transluminal angioplasty (PTA)-defined as the period from the first PTA to the next PTA or surgical revision within 12 months-as well as the clinical factors that contributed to the development of restenosis. (interventionalnews.com)
  • Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty. (biomedsearch.com)
  • The author recorded vascular murmurs before and after percutaneous transluminal angioplasty (PTA). (nii.ac.jp)
  • A randomized multicenter study of the outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis. (qxmd.com)
  • However, there are few data about the comparison of the patency rate of native arteriovenous fistula (AVF) to that of AVG in Korea . (bvsalud.org)
  • Arteriovenous fistulas (AVF) are the best hemodialysis vascular accesses, but their failure rate remains high. (bvsalud.org)
  • While a functioning arteriovenous fistula remains the gold standard for hemodialysis vascular access, failure rates remain unacceptably high, resulting in increased morbidity and mortality and higher health care costs," said Anthony J. Bleyer, M.D., Professor, Nephrology, Wake Forest Baptist Health, and lead author of the publication. (ptcommunity.com)
  • The PATENCY-1 results were the basis for Proteon's request to the U.S. Food and Drug Administration (FDA) for Breakthrough Therapy designation, which the FDA granted in May 2017 for increasing arteriovenous fistula secondary patency and use for hemodialysis. (ptcommunity.com)
  • The preferred form of vascular access for hemodialysis is a radiocephalic arteriovenous fistula, created when a surgeon connects a vein to an artery in the lower arm, resulting in a substantial increase in blood flow and vein dilation. (ptcommunity.com)
  • A Cimino fistula, also Cimino-Brescia fistula, surgically created arteriovenous fistula and (less precisely) arteriovenous fistula (often abbreviated AV fistula or AVF), is a type of vascular access for hemodialysis. (wikipedia.org)
  • Our work describing a role for vascular identity during adaptive remodeling has led us to investigate the response to fast-flow hemodynamic milieus such as those found in arteriovenous malformations and fistulae. (yale.edu)
  • Vonapanitase is an investigational drug intended to improve hemodialysis vascular access outcomes. (ptcommunity.com)
  • In hemodialysis, vascular access is used to remove the patient's blood so that it can be filtered through the dialyzer. (wikipedia.org)
  • Their results indicate that a poor patency rate is commonly associated with advanced age and diabetes mellitus. (interventionalnews.com)
  • Unfortunately, because of its poor patency and significant complication rate, it is also the "Achilles heel" of hemodialysis. (asnjournals.org)
  • Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial. (nih.gov)
  • However, the impact of multiple, compared with single, devices on branch artery patency has not been previously systematically studied. (ajnr.org)
  • The Kaplan Meier survival estimate of freedom from loss of primary patency at two years was 72% for BioMimics 3D subjects vs. 55.0% for the control arm. (vascularnews.com)
  • The main strategy of CABG is to obtain complete revascularization with the least morbidity and highest long-term patency rates. (clinicaltrials.gov)
  • The most frequent issue relates to problems with vascular access: stenosis, thrombosis, aneurysm, and infection. (interventionalnews.com)
  • Coupled with endothelial cell culture models, we now understand that shear stress, the frictional force generated by flowing blood, exerts a protective effect on the vascular endothelium to limit inflammation, thrombosis, and endothelial turnover [ 12 , 13 ]. (hindawi.com)
  • Data were collected by: graft type, coupler size, recipient vessels, intraoperative patency test, anastomosis time, need for revision of anastomosis, and graft failure (venous thrombosis or arterial failure). (isciii.es)
  • however, as a result of endovascular intervention, secondary patency rates at 12 months (87% vs 88%) and 18 months (87% vs 83%) were equivalent (P = .91). (qxmd.com)
  • Aggressive graft surveillance and endovascular treatment methods can yield equivalent long-term secondary patency rates between Vectra graft and TBB fistulas. (qxmd.com)
  • In an effort to better explain this very reproducible phenomenon, our analysis suggests that the difference between patency and limb salvage rates can be explained by a number of factors, the most important of which are the effects of reintervention and the severity of tissue loss present in the CLI population under study. (vasculardiseasemanagement.com)
  • These two factors, along with a few other facets that are unique to this complicated CLI cohort, help to explain the nature of the difference between the higher limb salvage rates and lower patency rates after revascularization. (vasculardiseasemanagement.com)
  • The presence of lower patency rates with discordant higher limb salvage rates in the same patient groups has prompted clinicians in the field to ask why this occurs and even to doubt the value of perfusion in CLI. (vasculardiseasemanagement.com)
  • If perfusion is a prerequisite to healing the threatened limb, it would make more sense if patency correlated well with limb salvage. (vasculardiseasemanagement.com)
  • This variance between lower patency and higher limb salvage rates is not an isolated issue, but rather a strong trend seen in the literature. (vasculardiseasemanagement.com)
  • The study showed a limb salvage rate of 86% and primary patency rate of 58% at 1 year. (vasculardiseasemanagement.com)
  • There is an important caveat in the patency vs limb salvage discussion. (vasculardiseasemanagement.com)
  • However, even when combining studies that utilize ankle brachial index (ABI), physical exam, Doppler, duplex, computed tomography angioplasty (CTA), and angiography, the gap may change a bit but the same wide variance between limb salvage and patency rates have been demonstrated. (vasculardiseasemanagement.com)
  • Higher primary and secondary patency, and higher limb salvage for below-knee bypass compared to standard ePTFE from 1-3 years. (goremedical.com)
  • Purpose: The purpose of this study was to assess the contribution of ongoing graft surveillance to maximize long-term patency of lower limb in situ saphenous vein bypasses. (elsevier.com)
  • The primary effectiveness endpoint was patency of the target lesion at 12 months and the primary safety endpoint was the composite of freedom from perioperative death from any cause at 30 days after the procedure and freedom for amputation and revascularization of the target lesion and limb-related death at 12 months. (cardiovascularbusiness.com)
  • The study of the Joint Vascular Research Group (JVRG) of UK found improved primary patency while the Scandinavian Miller Collar Study (SCAMICOS) found neither any effect on patency nor on limb salvage after bypass to below-knee arteries. (diva-portal.org)
  • The patency of intracranial perforating arteries after stent placement is unknown despite the general clinical use of intracranial arterial stenting. (ajnr.org)
  • We confirmed the patency of the lumbar arteries in this study by using normal rabbits. (ajnr.org)
  • After coating with 20 nm of gold, we examined the patency and the degree of re-endothelialization at the ostia of the lumbar arteries. (ajnr.org)
  • Q).What is the current perception and adoption of vascular stents for treating indications, including the iliac, femoropopliteal and infrapopliteal arteries in the lower extremity? (prnewswire.com)
  • however, unmet needs still exist with respect to patency and restenosis and treating challenging lesions in the femoropopliteal and infrapopliteal arteries. (prnewswire.com)
  • Inhibition of FXa with ZK-807834 decreases reocclusion and improves patency of recanalized arteries without increasing bleeding compared with heparin/aspirin. (aspetjournals.org)
  • In the current study, we evaluated the safety of the use of single and multiple flow-diversion devices in the rabbit aorta, in terms not only of chronic patency of adjacent small branch arteries covered by the devices but also of the degree of neointimal hyperplasia within the parent artery. (ajnr.org)
  • This suspension, once given to a patient intraarterially at the site of obstruction, is thought to have angiogenic potential down below, to develop new collateral arteries and to alleviate symptoms of peripheral vascular disease. (medgadget.com)
  • 5 6 7 In isolated ophthalmic arteries, NO is an important modulator of vascular tone, 8 and systemic NO-synthase inhibition decreases choroidal blood flow in animals 9 and humans. (ahajournals.org)
  • Zeller concluded that the ILLUMENATE Global study-one of the largest drug-coated balloon cohorts with independent core-lab and clinical event committee adjudication-has demonstrated the durable performance of the Stellarex drug-coated balloon at two years with a 72.4% primary patency rate and 85.3% freedom from clinically-driven target lesion revascularisation. (vascularnews.com)
  • Twelve-month assessments included primary patency, freedom from clinically driven target lesion revascularization (CD-TLR), Rutherford scoring, and walking impairment questionnaire. (onlinejacc.org)
  • GORE® PROPATEN® Vascular Graft, a leading prosthetic vascular graft for lower extremity revascularization, is specifically designed to reduce the risk of acute graft thrombotic failure. (goremedical.com)
  • The approval was based upon the results of the IMPERIAL trial, in which the Eluvia device was superior to the other device approved for the indication, a DES without a polymer coating (Zilver PTX, Cook Medical) in patency and target lesion revascularization at 12 months, according to a press release from Boston Scientific. (healio.com)
  • With respect to the post-PTA patency rate, although radiocephalic AVF appeared to result in a better patency rate than that of AVG, the difference was not statistically significant in either the log-rank test or Cox proportional hazard model," Yoshida and colleagues discuss. (interventionalnews.com)
  • Why do certain surgeons report a better patency rate with the GORE-TEX ® Stretch Vascular Graft? (goremedical.com)
  • New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate 1 of more than 96 percent. (bostonscientific.com)
  • Therefore, a significant clinical need remains for a device that is able to achieve more durable patency than PTA but does not require a permanent implant. (nih.gov)
  • With more than 10 years of performance, over 600,000 devices implanted, and over 2,000 limbs studied, the GORE® PROPATEN® Vascular Graft is a leading prosthetic bypass graft solution for proven clinical performance and low cumulative cost of care. (goremedical.com)
  • The GORE® PROPATEN® Vascular Graft is a leading prosthetic bypass graft solution for proven clinical performance and low cumulative cost of care. (goremedical.com)
  • The Scandinavian PROPATEN® Trial - 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses - a randomized clinical controlled multi-centre trial. (goremedical.com)
  • Biran R. Heparin Activity and Concentration Values from 52 and 96 Month Duration Clinical Explants of the GORE® PROPATEN® Vascular Graft . (goremedical.com)
  • Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. (prnewswire.com)
  • Focusing in on current clinical practices in the art and science of Vascular Access. (vascularaccess.com.au)
  • The study results suggested vonapanitase may improve both fistula use for hemodialysis and secondary patency (time to fistula abandonment), which are the co-primary endpoints in Proteon's ongoing Phase 3 PATENCY-2 clinical trial. (ptcommunity.com)
  • The PATENCY-2 clinical trial is fully enrolled and top-line data is expected in March 2019. (ptcommunity.com)
  • Israel21C is reporting that an Israeli company MultiGene Vascular Systems (MGVS) is conducting early stage clinical trials of its patient-specific cell therapy for peripheral vascular disease. (medgadget.com)
  • CONCLUSIONS: Based on the high primary patency, low stent fracture rate and significant clinical improvement, combined with refined stent design and long stent availability, the sinus-SuperFlex-635 self-expandable nitinol stent proves its value in the treatment of complex femoropopliteal lesions. (minervamedica.it)
  • These definitions and recommendations based on a critical evidence review and expert consensus are proposed to assist clinicians in ultrasound-guided vascular access and as a reference for future clinical research. (springer.com)
  • Vascular cannulation is a fundamental clinical skill. (springer.com)
  • Despite the magnitude of the clinical problem, relatively few new and effective therapies have been introduced into this field over the last two decades, resulting in a stagnation of vascular access care. (asnjournals.org)
  • We believe that an important barrier to developing new and effective therapies is the current lack of consensus among the different vascular access stakeholder groups (information on project structure below) regarding acceptable clinical trial end points for vascular access trials. (asnjournals.org)
  • We believe that evidence-based consensus among all involved stakeholder groups regarding vascular access clinical trial end points will serve as an important catalyst for interest, innovation, and investment in the field of vascular access through the creation of well defined clinical and regulatory pathways in this area. (asnjournals.org)
  • Our hope is that this quartet of manuscripts will facilitate a more well defined clinical trial pathway for testing out novel therapies for vascular access. (asnjournals.org)
  • In contrast to earlier observations, tibial patency was shown to impact on clinical outcomes in current randomized trials and is thus attributed more importance. (go.jp)
  • BioMimics 3D stented segments showed significantly greater curvature (P= 0.02) compared with the control, providing swirling blood flow and elevated wall shear, which may explain the longer term patency protective effect seen with BioMimics 3D. (vascularnews.com)
  • Misplacement of the arterial cannula or vascular pathology can lead to hemolysis or intimal damage with subsequent aortic dissection. (ebscohost.com)
  • We have previously shown that blood-derived endothelial outgrowth cells (EOCs) are effective in preventing restenosis and can restore vascular function in animal models of arterial injury. (ahajournals.org)
  • Common vascular access procedures in adults and children include peripheral venous, central venous and arterial cannulation. (springer.com)
  • Follow-up angiography was performed via the left femoral artery 1 week (n = 1) and 3 months (n = 7) after stent placement to evaluate patency of the lumbar artery. (ajnr.org)
  • Through GlobalData's analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. (prnewswire.com)
  • Q).As more bioabsorbable stents receive approval, how will new entrants impact the peripheral vascular stent market for the lower extremity? (prnewswire.com)
  • Analysis of the current and future market competition in the global peripheral vascular market. (prnewswire.com)
  • Kakkar V. The cephalic vein as a peripheral vascular graft. (springer.com)
  • The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (October 2012), CENTRAL (2012, Issue 10) and trials databases. (wiley.com)
  • This year at VIVA 18, the focus was on new advances for vascular intervention. (healio.com)
  • MRI provides information for characterizing the lesion, and it is also helpful in assessing the renal vascular pedicle. (medscape.com)
  • Cryopreserved homologous saphenous vein: early and late patency in coronary artery bypass surgical procedures. (springer.com)
  • The aim of the present study is to compare outcomes of the TBB fistula and the Vectra Vascular Access Graft. (qxmd.com)
  • Maintaining catheter patency and minimizing occlusions can be important steps in your efforts to enhance patient safety, improve patient outcomes, and reduce costs. (icumed.com)
  • abstract = "Subcutaneous vascular access ports allow for convenient serial blood sampling and the injection of pharmaceutical agents. (elsevier.com)
  • Theories concerning the pathogenesis of atherosclerosis have changed over the years, maturing concomitantly with our understanding of vascular biology. (hindawi.com)
  • PULMOTENSION integrated the top European centres in PH and lung vascular biology in a multidisciplinary approach, with the aim to combat and finally maybe even find a cure for PH. (europa.eu)
  • Endorsed by the World Interactive Network Focus on Critical Care Ultrasound (WINFOCUS), the Italian Working Group for Long-Term Venous Access (GAVeCeLT) and a consensus group at the World Conference on Vascular Access (WoCoVA). (springer.com)
  • Cryopreserved Venous allografts: effects of immunosuppression and antiplatelet therapy on patency and function. (springer.com)
  • Annualized PVS market revenue by type of stent and indication in the lower extremity, annual cost of disease and vascular stent adoption pattern data from 2010-2012 and forecast for seven years to 2019. (prnewswire.com)
  • If PATENCY-2 is successful in showing statistical significance (p≤0.05) for both of the co-primary endpoints, Proteon expects to file a Biologics License Application (BLA) with the FDA in the second half of 2019 and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the first half of 2020. (ptcommunity.com)
  • Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community. (evtoday.com)
  • Though we did not create the Stretch graft with improving patency in mind, some surgeons have reported greatly improved patency rates. (goremedical.com)
  • A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry. (harvard.edu)
  • More specifically, the present invention provides a subthreshold pulse generator for the local production of vascular endothelial growth factor. (google.com)
  • MultiGeneGraft is a long-lasting, biosynthetic vascular graft lined with the patient's own endothelial cells, modified to provide improved biocompatibility. (medgadget.com)
  • Our studies show, that in order to obtain prolonged patency, the graft inner lumen must be effectively coated with endothelial cells. (medgadget.com)
  • 7 papers documenting the patency of the cephalic vein for coronary bypass grafting and the largest series of cephalic veins for a lower extremity bypass were documented. (bestbets.org)
  • These data suggest the existence of a patency protective effect provided by the biomimetic characteristics of the BioMimics 3D nitinol stent resulting in haemodynamic and biomechanical performance advantages over straight nitinol stents," comments Zeller. (vascularnews.com)
  • Background Drug-coated balloons and drug-eluting stents improve patency of endovascular interventions with passive diffusion of antiproliferative drugs. (onlinejacc.org)
  • EMAILWIRE.COM, January 05, 2017 ) About the Vascular Stents Market A vascular stent is a mesh-like tube of thin wires developed using stainless steel or alloys. (emailwire.com)
  • At 12 months, the device met its primary endpoint demonstrating 93% primary patency and 100% secondary patency. (interventionalnews.com)
  • The primary effectiveness endpoint is one year primary patency. (vascularnews.com)
  • As previously reported, PATENCY-1 did not meet its primary endpoint of improved primary unassisted patency, compared to placebo (p=0.254). (ptcommunity.com)
  • However, for its pre-specified secondary endpoint, the trial showed a 34% reduction in the risk of secondary patency loss over one year, compared to placebo (p=0.048). (ptcommunity.com)
  • While the patency rates after vascular access construction between the two vascular access forms (radiocephalic AVF and AVG) was not significantly different in the multivariate analysis, they did show a significant difference in the log-rank test. (interventionalnews.com)
  • After two years of follow-up, the ILLUMENATE Global study has confirmed the durability of the Stellarex drug-coated balloon (Spectranetics/Philips) with primary patency rates comparable to those reported in randomised controlled trials. (vascularnews.com)
  • We aimed to study these factors, with the hypothesis that the surgeon's skills and facility practices would have an important role in primary failure and patency rates at 12 months, respectively. (bvsalud.org)
  • Results At 12 months, primary patency rates in DANCE-ATX and -PTA per-protocol populations were 78.4% (74.8% intent-to-treat [ITT]) and 75.5% (74.3% ITT), respectively. (onlinejacc.org)
  • Primary and assisted primary patency rates at 3, 6 and 12. (medworm.com)
  • Conclusions- Magnetic forces can be used to rapidly cover a vascular graft with paramagnetically labeled cells. (ahajournals.org)
  • Assisted patency rate: An access site which is patent after intervening manipulations (surgical or endovascular) intended to promote or reestablish patency. (clinicaltrials.gov)
  • The primary efficacy end point is primary patency at 12 months. (nih.gov)
  • This study examined the efficacy of FIRT for secondary VA patency in HD outpatients at our hospital. (biomedcentral.com)
  • We evaluated vascular patency and potential changes in preserved spleens after laparoscopic spleen-preserving distal pancreatectomy (SPDP) with conservation of both splenic vessels. (qxmd.com)
  • A combined criterion of proximal PSV of greater than 215cm/s or distal PSV of less than 25cm/s resulted in a sensitivity of 91.6% and specificity of 85.3% for detecting patency loss. (stanford.edu)
  • The CBAS Heparin Surface of the GORE® PROPATEN® Vascular Graft consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin's anticoagulant activity. (goremedical.com)
  • The CBAS Heparin Surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft (top) remains free of thrombus, while the 3 mm diameter control ePTFE graft (bottom) is covered with thrombus in an acute two-hour in vivo canine carotid artery interposition model. (goremedical.com)
  • Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. (goremedical.com)
  • Patency after 24 h was 100% in ZK-807834-treated and rTAP-treated dogs compared with 67% in control and 83% in heparin/aspirin-treated dogs. (aspetjournals.org)
  • Primary AVF patency rate at 1 year after HD introduction in the Juntendo University Hospital is 64%, which is similar to the mean AVF patency rate reported by the Japanese Association of Dialysis Physicians. (biomedcentral.com)
  • ICU Medical, Inc develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. (prnewswire.com)
  • BioMimics 3D, a nitinol stent with unique three-dimensional helical geometry, has been developed by Veryan, based on research by Colin Caro at Imperial College London into the link between blood flow mechanics and vascular disease. (vascularnews.com)
  • Features of vascular access contributing to extracorporeal blood flow. (biomedcentral.com)
  • FLOW ® 800 from ZEISS is a unique fluorescence application enabling visual analysis of vascular blood flow dynamics. (zeiss.com)
  • The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. (wiley.com)
  • To create a fistula, a vascular surgeon joins an artery and a vein together through anastomosis. (wikipedia.org)
  • A tenet of vascular care is that tissue needs adequate perfusion to survive. (vasculardiseasemanagement.com)
  • It is a safe and extremely effective method for evaluating parent artery integrity and aneurysm patency/residual perfusion in an experimental setting with rabbits and rats. (jove.com)
  • Ann Vasc Surg 41:225, 2017) as well as the role of the extracellular matrix in controlling vascular remodeling (Kuwahara et al. (yale.edu)
  • Overall goal of this project was to develop a tissue engineered vascular graft by implanting an electrospun tubular conduit into the peritoneal cavity to recruit autologous cells to it and provide the cells with the components of the hysiological environment prior to grafting the conduit into the artery. (fit.edu)
  • Fibrinolysis was induced with recombinant human tissue-type plasminogen activator (1.0 mg/kg i.v. over 1 h), and patency was monitored continuously for 24 h with an implanted Doppler probe. (aspetjournals.org)
  • In a vascular graft, the pores taper inwardly, providing a fluid-tight lumen wall structure that prevents leakage, yet promotes cellular ingrowth and natural tissue regeneration. (google.es)
  • 3. The method of claim 2, wherein the prosthesis is a vascular prosthesis and the lubricant property is selected to provide a pore size for tissue growth. (google.es)